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SUMMARY
Assessment of the relative potencies of compounds which inhibit the 
multiplication of herpes virus is rendered difficult by the fact that 
they have been investigated by different workers who were not using 
comparable test systems. The aim of this work was therefore to evaluate 
such test systems as could be used for studying the chemotherapy of 
herpes virus infections with particular reference to their suitability 
for determining relative potencies.
Both in vitro and iji vivo systems were investigated. Tissue culture 
methods included parallel observations of the time of appearance of 
cytopathic effect in the presence and absence of the test compound, 
carried out in tubes and raicrotitre plates. The compounds were also 
examined in plaque inhibition and plaque reduction tests, by the 
gradient plate technique, and by determining the reduction in virus yield 
produced by the test compound in single-cycle experiments. The gradient 
plate technique gave a visual indication of the minimal inhibitory 
concentration. With the other methods dose-response lines were obtained, 
the most satisfactory being given by the plaque reduction method.
Cytarabine was the most active compound, the ID50 with a standard strain 
of type 1 herpes being 0.23 pM. The values for the other compounds were 
0.76 pM for trifluorothymidine, 0.89 pM for idoxuridine, 14.96 pM for 
vidarabine and 20.89 pM for diaminopurine arabinoside. The compounds fell 
in the same order in tests with type 2 strains, except that 2 strains were 
found to be insensitive to trifluorothymidine and diaminopurine arabinoside.
The in vivo models used were herpetic encephalitis in mice and 
herpetic keratitis in rabbits. Dose-response lines could be obtained 
in mice by taking the mean reciprocal survival time as the response, but 
they were not as satisfactory as those obtained by plaque reduction.
The keratitis model could not be used for determinations of relative 
potency, but it was satisfactory for assessing the therapeutic effect 
of different concentrations of the test compound, and thus for ranking 
comparable solutions of the different compounds in order of activity. 
Satisfactory clinical cure was obtained with all compounds regardless 
of their relative potencies as determined in tissue culture.
From the results of both in vitro and in vivo test systems it was 
possible to demonstrate variations in sensitivity between types and 
between strains of the same type. There are several reports in the 
literature that type 2 strains of herpes virus are less sensitive 
than type 1. In the present work this was found to be not the case, 
since there was a wide overlap in the sensitivities of the strains of 
the two types, with some type 2 strains being considerably more sensitive 
than those of type 1.
The present studies have thus established satisfactory test methods 
for the quantitation of the relative potency of the standard anti-herpes 
compounds, which will be valuable in the assessment of the antiviral 
potential of compounds to be discovered in the future.
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INTRODUCTION
d
The name herpes is derived from the Greek verb ep'ireiv 
to creep, and has been used for about 2,500 years to describe spreading 
lesions of the skin. The causative agent of such infections is a virus 
which produces vesicular lesions or fever blisters on the mucous membranes, 
the muco-cutaneous junction and the skin. The areas involved are mainly 
oral or genital although the eyes are often involved and systemic illness 
may occur. The virus was first isolated from a skin infection of the
lip which is called by the dermatologists herpes simplex, and therefore 
the virus is commonly called herpes simplex virus. This name is 
inconsistent, as the same virus is known to be the causative agent of 
other skin infections, for example herpes febrilis, herpes genitalis and 
herpes progenitalis. Therefore it was felt that the term herpes virus 
should be used throughout this work, thus avoiding this inconsistency, 
and also any confusion with herpes zoster, which is caused by a different 
although related virus.
1.1 MORPHOLOGICAL AND CHEMICAL CHARACTERISATION OF HERPES VIRUS
The structure of the herpes virion can be visualised in the electron 
microscope by negative contrast staining with phosphotungstic acid.
It consists of a spherical core 75 nm in diameter enclosed by a stable 
capsid measuring 100 nm in diameter, in the form of an icosahedron.
The capsid consists of 162 hollow, elongated capsomeres (9 - 10 nm x 
12 - 13.5 nm), of which 150 are hexagonal and 12 are pentagonal 
(Wildy et al., 1960). The capsid is surrounded by a less stable
envelope 130 - 180 nm in diameter (Kaplan, 1969). Particles without 
an envelope are called "naked particles" and particles without a central
core are called "empty particles". The central core has been found to 
consist of an inner core 35 nm in diameter known as the nucleoid, which is 
sensitive to deoxyribonuclease (Epstein, 1962), and therefore contains DNA.
An analysis of the chemical constituents of purified preparations of 
virus by Russell et al. (1963) shows that the virion consists of 7% DNA,
1.7% carbohydrate, 22.3% phospholipid and 69% protein. The viral DNA is 
double stranded with a density of 1.727 to 1.729 g/ral, depending on type, 
and the molecular weight is 68 x 10 daltons (Russell and Crawford, 1963).
1.2 CULTIVATION
Herpes virus was first cultivated in the rabbit cornea in 1914 
(Gruter, 1924), and Lipschutz (1921, 1932) reported mild and severe ocular 
infections as a result of intraocular inoculation of rabbits with different 
strains of herpes virus. At about the same time herpes virus was also 
shown to grow in other rabbit organs such as the testes, liver and 
trachea (Goodpasture and Teague, 1923). Furthermore, Parker and 
Nye (1925) demonstrated that virus would grow in pieces of rabbit 
testicular tissue in culture. The virus has subsequently been successfully 
grown in a variety of animal systems, in embryonated eggs and, of course, 
in a wide range of cell cultures.
1.2.1 Cultivation in animals
Since the early work on the rabbit eye subsequent studies have been 
performed with increasingly sophisticated techniques. For instance,
Kaufman et al. (1962) and Jones et al. (1968) both demonstrated that 
controlled scarification and inoculation of the corneal epithelium 
allowed the development of specific dendritic lesions 1 - 3 days later.
This type of procedure has formed the basis of many contemporary studies.
Mice are also extremely susceptible to experimental infection with 
herpes virus. For instance, as early as 1929, Andervont found that 
intracerebral inoculation of mice was a most effective way of demonstrating 
infection, because it produced encephalitis and subsequent death.
Infections also resulted from inoculation by subcutaneous, intraperitoneal, 
intravenous and corneal routes. Lennette and Koprowski (1944) reported 
that mice over 14 days old were considerably less susceptible to infection 
than were younger mice. In addition to mice and rabbits, herpes virus 
may also be cultivated in other species of rodents. Thus rats have been 
infected by the intraocular route (Teissier et al., 1944) and by intracerebral 
inoculation (Wenner, 1944), and hamsters (Zarafonetis and Smadel, 1944), 
guinea-pigs (Urbain and Schaeffer, 1929), and cotton rats (FIorman and 
Trader, 1947) have all been experimentally infected by various routes.
1.2.2 Cultivation in embryonated eggs
Goodpasture et al. (1931) were the first to find that herpes virus 
caused the formation of characteristic pocks on the chorioallantoic membrane 
of the embryonated hen's egg. They noted that the pocks were produced on 
10 - 13 day old membranes about 72 hours after inoculation. Histological 
examination of infected membranes showed intranuclear inclusions and 
giant cells (Dawson, 1933) and also mesodermal inflammation (Coriell 
et al., 1949; Nil and Kamahora, 1963). When virus was introduced into 
the allantoic fluid, cutaneous, pharyngeal, amniotic and peritoneal 
infections of the embryo were induced which showed similar cytological 
changes to those found in the chorioallantoic membranes (Anderson, 1940).
1.2.3 Cultivation in cell culture
The range of laboratory cell cultures susceptible to herpes virus 
largely reflects the natural host range of the virus. The monolayer cell 
cultures first demonstrated to support growth of the virus were chick 
embryo fibroblast cells (Stulberg and Schapira, 1953), Earle’s mouse L cells 
(Scherer, 1953) and later HeLa cell cultures (Scherer and Syverton, 1954). 
Herpes virus was later found to produce discrete plaques under either 
solid or semi-solid media overlays in a number of cell lines; rabbit 
kidney cells (Kaplan, 1957), HeLa cells (Farnham, 1958), human amnion 
cells (Osterhout and Tamm, 1959) and chick embryo fibroblast cells 
(De Maeyer and Schonne, 1964).
1.3 SUB-DIVISION OF HERPES VIRUS STRAINS
Differences in pathenogenicity have long been known to exist among 
different strains of herpes virus. However, Burnet et al. (1939), in 
agreement with earlier workers, failed to show any significant antigenic 
differences between the strains of herpes virus which they tested.
Slavin and Gavett (1946a, b), however, following their work on genital 
herpes, detected antigenic variations in the mouse neutralisation test 
between the established laboratory strain HF, derived from a recurrent 
oral strain, and two strains of genital origin. Similar results were 
obtained by Florman and Trader (1947) who, using the neutralisation test 
on the chorioallantoic membrane, found differences between certain 
neurologically isolated strains and oral strains. Hayward (1950) and 
Kilbourne and Horsfall (1951) failed to show an antigenic difference 
between various strains of herpes virus and claimed that differences 
reported by others were probably without useful significance. Their
conclusions, however, were to be expected as the strains they tested 
were all of oral origin; their comments consequently had little impact. 
Complement-fixation techniques were successfully employed by Sheva and 
Robins (1953) and Womack and Hunt (1954) to demonstrate antigenic 
differences. Similar results were obtained by Jawetz et aJL. (1955), who 
used serum dilution neutralisation tests in mice to compare strains of 
various origins with the standard HF strain. Three strains differed 
from the majority of strains, and of these three one strain was from an 
upper thigh infection. At the same time Jawetz noted that some strains 
produced larger pocks on the chorioallantoic membrane in comparison with 
the majority of herpes virus strains which he tested. Similar pock size 
differences were also observed by Wildy (1955), and later by Schneweis 
(1962a). Complementary to these observations were those of Gray et al. (1958) 
who found that different strains of herpes, the origins of which were not all 
fully described, produced distinct types of cytopathic effect in HeLa cells. 
Some strains induced the formation of proliferative foci of rounded cells, 
whereas other strains produced open, non-proliferative groups of rounded 
cells with multinucleate giant cells. Scott et al. (1959) and 
Schneweis (1962b) also noted these differences.
The accumulation of evidence of differences between herpes virus 
strains led Shubladze and Chzhu-Shan (1959) and Shubladze et al. (i960) 
to make a detailed study of the differences. Although they failed to 
detail fully the origins of the virus strains used, they found that 
strains of herpes virus could be divided into three distinct serotypes, 
on the basis of the results of neutralisation tests performed in mice, 
and referred to them as L^, K and US. Schneweis (1962a) obtained similar 
results when he examined 30 strains of herpes virus, which included the 
three distinctive strains isolated and studied by Jawetz et al. (1955).
Neutralisation as well as complement-fixation techniques were employed 
for this work. Plummer (1963) examined representatives of the three 
groups and claimed that the third type, US, described by Shubladze and 
Chzhu-Shan, was not a herpes virus at all but was related to Japanese B 
encephalitis virus.
Antigenic differences between 15 strains of herpes virus were 
subjected to more detailed comparison in kinetic neutralisation tests 
with homologous and heterologous antisera (Ashe and Scherp, 1963). These 
workers also attempted to relate the differences which they observed to 
the years of virus isolation, but no obvious correlations were found.
The tissue culture studies reported by Gray et al. (1958) led to 
attempts to find further biological differences between strains of herpes 
virus. Hoggan and Roizman (1959) detected micro- and macroplaque- 
producing strains in FL cells. Similar results were obtained by 
Rapp (1963) in rabbit kidney and human amnion cells.
The major breakthrough in the sub-division of herpes virus strains 
was made by Pauls and Dowdle (1967), who used microneutralisation to 
separate 24 strains of herpes virus into 2 serological types. They 
classed 79% as type 1 and 21% as type 2. In subsequent work on 
91 strains, including the majority of the original 24 strains, a 
correlation was found between the antigenic type and the site of 
isolation (Dowdle et al., 1967). Thus of t h e 91 strains, 42 which were 
isolates of the adult genital tract were serologically classified as 
type 2 virus, and the remaining 49 strains which were all serologically 
classified as type 1 were all oral or cutaneous isolates not related to 
the genitalia. It became obvious at the time that this correlation was 
made why there had been such extensive discussions in the past.
Slavin and Gavett (1946a, b), and Florman and Trader (1947) showed
serological differences between genital and oral strains and therefore 
found distinctive strain differences. The failure of some of the 
subsequent workers to establish consistent differences is reflected in 
their choice of strains, all of which were of a typical type 1 virus 
origin. Workers who did find differences failed to correlate them 
with the sites of virus isolation.
Nahmias et al. (1968) found that their type 1 and 2 strains, which 
were characterised serologically, produced pocks of differing sizes on 
the chorioallantoic membrane. Type 2 strains produced large pocks 
(> 0.5 mm) and type 1 strains produced small pocks (< 0.5 mm). The 
histology of the infected membranes was studied at the same time and 
it was found that type 1 pocks could be easily picked off and only 
invaded the ectoderm, whereas type 2 pocks were found to invade the 
endo-, meso- and ectoderm layers of the membrane. Other histological 
differences between the two types were also found, and are summarised 
in Table 1.1.
Another development concerned the use of immunofluorescent antibody 
techniques in the diagnosis of herpes infections. Nahmias et al. (1969) 
applied a direct immunofluorescence test with dilutions of fluorescein- 
conjugated rabbit type 1 and type 2 antisera, and demonstrated that 
HEp-2 cells infected with type 1 virus reacted with both homologous 
and heterologous sera. The fluorescence took the form of fluorescent 
granules and perinuclear staining. However, cells infected with 
type 2 virus only reacted with the homologous antiserum and in this 
case both nuclear and perinuclear staining occurred, but with no 
fluorescent granules. This separation of types correlated with results 
previously obtained by microneutralisation, and was later confirmed 
by Nahmias et al. (1971), when the test was applied to infected mice 
and directly to clinical isolates.
TABLE 1.1 HISTOLOGICAL DIFFERENTIATION OF POCKS ON THE CHORIOALLANTOIC 
MEMBRANE OF EMBRYONATED EGGS AFTER INFECTION WITH 
HERPES VIRUS TYPES 1 AND 2 (after Nahmias et al., 1968)
Characteristic 
Site of involvement
Ectodermal hyperplasia
Congestion
Haemorrhages
Necrosis
Erosion
Fibroblastic hyperplasia 
Inflammatory cells
Type 1 
Ectoderm mainly
Marked
Mild
Rare
Rare
Mild
Slight
Few (monocytes)
Type. ,2
Entire thickness (ectoderm, 
mesoderm and endoderm)
Moderate
Marked
Common
Common
Marked
Marked
Marked (mixed monocytes 
and polymorphonuclear 
leucocytes)
Multinucleate giant cells Rare 
Intranuclear inclusions Occasional
Common
Common
Indirect immunofluorescent staining techniques with infected 
BHK cell cultures also demonstrated differences between established 
type 1 and type 2 strains (Geder and Skinner, 1971). These results 
were confirmed by Leinikki (1971), who successfully typed clinical 
isolates cultivated in VERO cells. He compared his results with the 
biological properties of the strains in VERO cells and found that 
type 1 strains produced small plaques and type 2 strains produced large 
plaques. Figueroa and Rawls (1969) obtained similar results in chick 
embryo fibroblast cells, and in their attempts to find further biological 
differences between type 1 and type 2 strains they found that the former 
replicated poorly and even when plaques were produced they were small; 
type 2 strains, on the other hand, were found to replicate well and 
produced substantially larger plaques. These results were confirmed by 
Lowry et al. (1971), who considered this technique to be a reliable 
biological marker for typing herpes virus strains.
In an investigation of 31 strains of herpes virus for their ability 
to produce cytopathic effects in VERO cells at various temperatures, 
Ratcliffe (1971) found that type 1 strains maintained a high infectivity 
when cultivated at temperatures between 35°G and 40°C. Type 2 strains, 
however, failed to replicate efficiently above 39°C. These results 
were found to apply to both established laboratory strains and to freshly 
isolated strains, and were confirmed by Longson (1971) as well as 
Thouless and Skinner (1971). Confirmation was also obtained by Crouch 
and Rapp (1972) in human embryo lung and fibroblast cells, but the 
difference was found to be less marked than in rabbit kidney cells.
With such substantial differences between type 1 and type 2 herpes 
virus more recent research has been directed towards demonstrating 
biochemical and enzymological differences. One such difference was
an increase in thymidine kinase activity of infected BHK 21 cells, an 
enzyme known to be virus specific (Klemperer et al., 196?). The growth 
kinetics and the amount of enzyme produced were the same for both types 
of virus but marked differences in the stability of this enzyme were 
found (Thouless and Skinner, 1971). Thus the activity of enzyme 
extracted from type 1 infected cells persisted after incubation at 40°C 
for one hour, whereas the activity of the enzyme induced by type 2 fell 
to almost zero during the same incubation period.
This technique, along with the biological features of pock size, 
plaque appearance and site of isolation, and the serological data obtained 
from neutralisation tests, has recently been used in a comprehensive study 
by Plummer et al. (1974) to determine whether there are any intermediate 
types. They reported good correlation between all typing methods and 
found no evidence for intermediate types; all 60 strains tested fell 
into either type 1 or type 2.
1.4 CLINICAL FEATURES OF HERPES INFECTIONS
The range of infections caused by herpes virus is listed in Table 1.2, 
and falls into one of two classes, either primary infection where the 
patient has no circulating neutralising antibodies, or recurrent infections 
in the face of circulating neutralising antibodies.
The typical primary signs are characteristic local lesions occurring 
on the mucous membranes and skin of the buccal and genital regions, and 
such infections may lead to systemic illness and even death. The lesions 
take the form of vesicular eruptions which eventually scab and heal 
without scarring. Systemic involvement when it occurs usually does so 
after the development of local lesions. However, this is not necessarily
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the case, and such clinical variation may make diagnosis difficult.
An important group of infections involves the eye, and may be due 
to either primary or recurrent disease. The extent of involvement may 
be either deep or superficial, both presenting a serious hazard to sight. 
Superficial infections usually only involve the conjunctiva (conjunctivitis) 
and the corneal epithelium (keratitis) frequently also with chemosis and 
oedema of the eye lids. Corneal involvement is presented as characteristic 
dendritic ulcers developing in the corneal epithelium which may extend 
to form large geographic ulcers (Fig. 1.1), and such infections are 
typically acute but normally self-limiting, subsiding after 2 - 3  weeks 
(Ormsby, 1957). A quarter of the cases which start as superficial 
lesions develop into deep infections (Thygeson and Kimura, 1957), and 
the incidence of this complication is particularly high in the newborn 
because of the avascular nature of the cornea and the absence of 
circulating antibodies.
There are two main categories of deep involvement, disciform 
keratitis and hypopyon keratitis. The former condition starts as a 
benign ulceration of the central two-thirds of the cornea, followed by 
oedema of the stromal fibres, and results in a disciform keratitis.
Such infections persist for 2 - 3  months and may result in corneal 
rupture and secondary infection.
Hypopyon keratitis often follows the steroid treatment of severe 
geographic ulceration leading to corneal anaesthesia, a feature which 
distinguishes herpetic hypopyon from those of bacterial or fungal aetiology. 
The viruses usually implicated in such infections are strains of herpes 
virus type 1, but type 2 strains have also been found to be associated 
with eye infections. The neurotropic nature of this type may lead to 
subsequent damage to the optic nerve, with serious consequences to the 
quality of sight.
Fig. 1.1 Geographic ulceration of the cornea of a rabbit
caused by strain 11 of type 1 herpes virus. The cornea 
was stained with fluorescein.
Recurrent infections of the eye are normally much less severe than 
primary infections, and typically have a superficial nature.
A serious disease with which herpes virus type 2 has been implicated 
is certain types of carcinoma of the cervix, but the evidence for this 
is essentially derivative and is based on serological as well as clinical 
data. Thus, women who have had a history of genital herpes show an 
increased incidence of cervical dysplasia, carcinoma in situ and invasive 
carcinoma (Naib et al., 1966). Furthermore, the incidence and level of 
type 2 antibodies in such women is much greater than in those with 
tumours at other sites (Royston and Aurelian, 1970; Rawls et al., 1969). 
However, criticisms of these reports were levelled by Melnick and 
Rawls (1970), Plummer and Masterson (1971) and Rawls et al. (1969), who 
pointed out that the data were derived only from studies of negro women 
of a low socioeconomic class. Thus, evidence to substantiate a 
relationship between herpes virus type 2 infection of the cervix and 
subsequent carcinoma of the cervix is by no means well founded. At best 
the association is based upon circumstantial evidence and may merely 
reflect the higher incidence of such infections and cervical cancer in 
sexually promiscuous women. To prove that type 2 virus is the 
aetiological agent in cervical cancer direct evidence would be required; 
for example, not only the detection of virus-specific antigens in 
tissues of such patients, but also the presence of a cell-mediated 
immune response to the virus. However, this alone would not rule 
against the virus being present in a passenger capacity and merely 
activated by some other force.
1.5 TREATMENT OF HERPES INFECTIONS
Pliny (1601 translation) was probably referring to fever blisters 
or cold sores, now known to be caused by herpes virus, when he 
recommended "For which kind of ulcers snails, bruised shels and all, 
bee passing good ... Moreover the fat of a dragon dried in the sun 
is very effectual, like the brains of a Cocke ....." This bizarre 
treatment was the forerunner of many attempts to control the condition.
Recovery from infections with herpes virus, unlike recovery from 
infections with other viruses, is not associated with complete immunity. 
The virus may remain latent and recurrent infections may occur even 
though neutralising antibody is detectable in the serum. Antibody to 
herpes virus is found in 40% of newborn children up to 4 months due to 
placental transfer of maternal antibodies. This level falls to about 
10% between the ages of 4 months and 4 years, after which time it 
increases with age so that 60% of adults possess antibodies to herpes 
virus (Scott et al., 1952; Buddingh et al., 1963; Yoshino et al., 1962).
Recovery from both primary and recurrent infections is the result 
of both cell-mediated and humoral immunity. Therefore patients suffering 
from an immunological deficiency or patients under immunosuppressive 
treatment tend to get a more severe illness than do normal individuals.
A delayed hypersensitivity reaction may occur in convalescent herpetic 
patients due to a soluble antigen of the virus. This may induce 
erythema multiforme seven to ten days after the onset of a herpes virus 
infection. There is a general impression that such a hypersensitivity 
reaction plays a part in the recovery from herpes virus infections 
because of the severity of illness when cell-mediated immunity is 
depressed, and the fact that patients with hypo- or agammaglobulinaemia 
and normal cell-mediated immunity do not have severe illness. It seems
probable, therefore, that patients suffering from erythema multiforme 
after an initial herpes infection are experiencing a delayed hypersensitivity 
reaction. For similar reasons patients with recurrent herpes virus 
infections which become more severe with each recurrence in relation 
to the amount of virus produced, probably experience the same delayed 
hypersensitivity reaction. Therefore for these patients desensitisation 
by inoculation of a killed herpes virus vaccine is of possible therapeutic 
value.
At the beginning of the twentieth century much interest was directed 
towards vaccination, and many workers including Fournier and Levaditi (1928) 
attempted to treat recurrent herpetic lesions by this method. For this 
purpose, virus grown in rabbit or mouse brain, or on the chorioallantoic 
membrane, was inactivated with heat or formalin. Alternatively the 
inoculation of vesicle fluid was carried out, although with disastrous 
results, inducing a severe recurrent infection at the site of inoculation 
(Paulian, 1932). Studies on vaccination were taken up again by 
Lepine et al. (1964), with Henocq et al. (1964), who used virus grown in 
sheep embryo kidney cell cultures to produce an inactivated vaccine by 
ultraviolet irradiation. This was tested in rabbits and found to induce 
the development of both neutralising and complement-fixing antibodies.
Tests of the vaccine in 20 subjects with recurrent herpes showed 
improvement in 18.
The treatment of herpes virus infections therefore remains a 
therapeutic rather than a prophylactic problem, and with the increase in 
the understanding of viral replicative mechanisms and cell metabolism, 
the prospects for viral chemotherapy are encouraging. However, herpes 
virus infections may be complex, involving not only viral damage but 
inflammatory reactions and possibly secondary bacterial invasion.
Histamine would be released if inflammation occurs and therefore 
antihistamines would be used in treatment, possibly coupled with anti­
bacterial compounds to prevent the secondary invasion of the open herpetic 
lesions.
Topical antiherpes compounds may be used for the treatment of 
surface infections such as cold sores, stomatitis, gingivostomatitis, 
ocular lesions and whitlows. Idoxuridine is the most frequently used 
compound, either as a 40% solution in dimethylsulphoxide or in an 
orabase ointment. In severe cases of ocular herpes cauterisation may 
be required, and in the case of deeper involvement steroids may be 
indicated. These are normally contraindicated because of the lytic 
nature of herpes virus infections, which would be severely aggravated 
by such treatment.
More severe infections such as herpetic encephalitis, generalised 
herpes infections and genital herpes demand more general measures, such 
as systemic administration of 1-p-D-arabinofuranosylcytosine. This has 
been shown to be efficacious in systemic treatment, and such treatment 
is often accompanied with the topical treatment of any external lesions.
Most of the compounds used at present have either been found to be 
effective by chance, or have been used because of their known capacity 
to inhibit certain properties, e.g. adsorption, penetration, nucleic acid 
replication, and release. However, the treatment of human virus 
infections has always presented problems; for example, the treatment 
time is often limited by acute self-limiting courses of infection, and 
also the replication of viruses within the host cell presents a problem 
of drug toxicity to the cell. In many virus diseases virus replication 
has reached a maximum by the time symptoms appear, which affords no time 
for specific treatment. Examples of such diseases are rabies, yellow
fever, poliomyelitis and infective hepatitis. Treatment is feasible, 
however, with more protracted infections (measles, chickenpox and certain 
adenovirus infections) or external infections of the eye or skin due to 
herpes, vaccinia or adenoviruses.
The aim of antiviral chemotherapy is to discover compounds which 
prevent viral replication without significant damage to the host cell 
or interruption of normal cell function. Ideally the active compound 
should exert its effect either on the mechanism of viral adsorption and 
penetration, or on one or more of the processes involved in the replication, 
maturation or release of the virion.
Inhibition of viral adsorption has been obtained with amantadine 
hydrochloride (Davies et al., 1964), which prevents the attachment of 
influenza virus to cell surfaces. The use of such compounds is limited, 
however, especially when virus infection spreads by cell to cell contact, 
and in the case of viruses which do not appear to require specific sites 
of attachment•
Several chemical inhibitors have been used more or less successfully 
against viral replication; these fall into three main categories - 
DNA, RNA and protein synthesis inhibitors. The problem here is that 
virus replication is closely integrated with the metabolic functions of 
the host cell, and therefore inhibition of viral activity may also 
inhibit cell function; however, virus-specific enzymes are known to be 
produced during virus replication and specific inhibitors may be directed 
against them.
1.6 ANTIVIRAL ACTIVITY OF SUBSTITUTED PURINES AND PYRIMIDINES
It was decided in this study to examine the antiviral activity of 
the substituted pyrimidines 5-iodo-2'-deoxyuridine, 5-trifluoromethyl-21- 
deoxyuridine and l-(3-D-arabinofuranosylcytosine, and the substituted 
purines 9-p-D-arabinofuranosyladenine and 9-p-D-arabinofuranosyl-2,6- 
diaminopurine.
1.6.1 5-Iodo-2f-deoxyuridine (lUdR)
The search for active compounds has long been focussed upon 
analogues of naturally occurring metabolites possessing highly selective 
virus-inhibiting activity. This led to the discovery of 5-iodo-2*- 
deoxyuridine (IUdR), which was found to be very active against certain 
DNA viruses. The structure of IUdR is shown in Fig. 1.2. The activity 
of compounds of this class was thought to be associated with the fact 
that the Van der Waals radii of the substituents in the 5- position 
created a resemblance to that of thymidine (Table 1.3). Compounds
o o
possessing radii of between 1.80A to 2.44A are capable of replacing 
thymidine in the production of viral DNA, thus producing a fraudulent 
DNA code.
IUdR was first synthesized by Prusoff (1959), who found that it 
inhibited the growth of Streptococcus faecalis, and later Herrmann (1961) 
found that both IUdR and BUdR, analogues of thymidine, were active against 
herpes virus and vaccinia virus by plaque inhibition. Subsequently 
activity against many other DNA viruses was shown (Table 1.4).
IUdR, as well as inducing the formation of a fraudulent code, also 
inhibits certain DNA synthesizing enzymes, including thymidine kinase, 
thymidylate kinase, nucleoside diphosphate reductase and DNA polymerase 
(Goz and Prusoff, 1970). However, Prusoff and his colleagues also
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Fig. 1.2 Structural Formulae of the Pyrimidine Nucleosides Used
TABLE 1.3 VAN DER WAALS RADII OF SUBSTITUENTS IN ANALOGUES OF THYMIDINE
Radical
H
F
Cl
Br
CH3
I
CF3
NHCH_
Van der Waals radius
O
A
1.20
1.35
1.80
1.95
2.00
2.15
2.44
Compound
2*-deoxyuridine (UdR)
5-fluoro-2f-deoxyuridine (FUdR) 
5-chloro-2f-deoxyuridine (ClUdR) 
5-bromo-2*-deoxyuridine (BUdR)
5-methyl-2f-deoxyuridine (thymidine)(TdR) 
5-iodo-2'-deoxyuridine (IUdR)
5-trifluoromethyl-2’-deoxyuridine
(CF3UdR)
5-methylamino-2f-deoxyuridine (MAdU)
TABLE 1.4 ANTIVIRAL SPECTRUM OF IDOXURIDINE
Nucleic acid 
DNA
Group
Poxvirus
Adenovirus
Herpesvirus
Papovavirus
Virus
Vaccinia
Adenovirus
Herpes
Varicella-zoster
Pseudorabies
Bovine rhinotracheitis
Cytomegalovirus
Polyoma
SV40
RNA None None
concluded that substitution into the viral DNA to replace the thymidine 
moiety was the most frequently observed mode of action of IUdR, and the 
blocking of synthesizing enzymes was of less significance.
The activity of IUdR against herpes virus iji vitro led to studies 
of its efficacy against herpetic keratitis in the rabbit (Kaufman et al., 1962b 
Kaufman and Maloney, 1963a). Subsequent work showed that the compound 
was also active against’ dendritic and other surface infections, but not 
when stromal and deeper involvement occurred (Furgiuele et al•, 1962;
Corwin et al., 1963; Perkins et al., 1962). Clinical trials in man were 
carried out with 0.1% - 0.5% solutions in the form of eye drops 
administered hourly through the day and at two-hourly intervals throughout 
the night (Kaufman, 1962; Corrigan et al., 1962). The compound was 
apparently effective, but doubt was cast upon these findings when 
Ey et al. (1964) reported that the activity observed for IUdR was due 
to the inhibition of cell metabolism, thus preventing viral replication.
Thus the elimination of virus was largely the consequence of development 
of immunity. However, subsequent studies by Patterson and Jones (1967) 
soon allayed these doubts, and IUdR was again accepted and recommended 
as the standard treatment for both primary and recurrent herpes keratitis.
Dyan and Lewis (1969) showed that the compound may produce a mild toxicity 
in the eye, with stinging, pruritus, inflammation and photophobia, but 
these conditions recede on cessation of treatment and are not considered 
a danger.
Similar topical administration of IUdR was studied in the treatment 
of cutaneous and genital herpes infections. In double-blind trials 
against cold sores (Juel-Jensen and MacCallum, 1964; Burnett and Katz, 1963) 
the compound proved inactive, and an IUdR cream was also found inactive 
against cutaneous herpes (Kibrick and Katz, 1970). Juel-Jensen and
MacCallura (1965) explained that this inactivity was associated with the 
low solubility of IUdR, so that insufficient compound reached the infected 
site, and they overcame this by spraying the infected site with a jet gun 
loaded with solution. However, a 5% IUdR solution in the solvent 
diraethylsulphoxide (DMSO) superseded the spray gun technique, and was 
found to give good penetration of the compound, which then showed 
substantial activity against superficial herpes infections (MacCallum and 
Juel-Jensen, 1966). *
DMSO alone has some activity against cutaneous herpes infections, 
as well as being known to be bacteriostatic, and it is not completely 
clear what part the solvent has in antiviral activity (MacCallum and 
Juel-Jensen, 1966; Juel-Jensen et al., 1970; Juel-Jensen, 1971).
The systemic treatment of herpetic infections has not been so 
successful, because IUdR is rapidly broken down to 5-iodouracil which 
is quickly excreted, and in these cases there is a need for continuous 
infusion, at near toxic levels. A dosage of 80 - 100 mg/kg/day for 
5 days was normally tolerated without toxicity (Calabresi et al., 1961), 
which was monitored throughout treatment by looking for typical 
manifestations such as leukopenia, thrombocytopenia, stomatitis and 
alopecia, which all result from the effect of IUdR on young actively 
dividing cells (Calabresi et al., 1963). Isolated reports of the 
successful treatment of herpes encephalitis have been made, and 
Rappel and Brihaye (1969) reported 9 successful treatments from 
11 cases. The effectiveness of such treatment was not accepted by 
Tomlinson and MacCallum (1970), who stated that "there is so far 
no convincing evidence that IUdR influences the course of clinical 
herpes encephalitis." Illis and Merry (1972) more recently reviewed 
cases of herpetic encephalitis treated with systemic IUdR and also
concluded that it was of little use as it is rapidly broken down and 
excreted. Furthermore it has been shown by radioactive labelling 
techniques that insufficient drug reaches the brain and cerebrospinal 
fluid (Breeden et al., 1966; Clarkson et al•, 1967).
Resistance of herpetic infections to IUdR has been reported and 
has caused some concern amongst the medical profession. Kaufman and 
Maloney (1963b) stated that a patient with herpes keratitis failed to 
respond to IUdR treatment. Furthermore, resistant strains have been 
isolated which have failed to respond to IUdR under experimental 
conditions in vivo (Laibson et al., 1963). Resistant strains of virus 
have been produced artificially by serial passage in cell culture in 
the presence of IUdR (Buthala, 1964; Underwood et al., 1964). Prior 
treatment, however, is not a necessity for producing a resistant strain.
At present resistance to other anti-herpes virus compounds has not 
been reported, thus treatment with ara-C or trifluorothymidine has 
always proved successful in cases resistant to IUdR.
1.6.2 1-p-D-Arabinofuranosylcytosine (cytosine arabinoside, ara-C)
1-p-D-Arabinofuranosylcytosine (ara-C) was first synthesized by 
Walwick et al. (1959), and differs from the thymidine analogues only 
by having the sugar residue arabinose in place of ribose or deoxyribose 
(Fig. 1.2).
It was synthesized as an antitumour compound, and was later found 
to be effective in cell culture studies against a number of DNA viruses 
including herpes virus (Underwood et al., 1964), and varicella- 
zoster virus (Rapp, 1964), although inactive against adenoviruses and 
RNA viruses (Table 1.5).
Comparative studies of IUdR and ara-C revealed that ara-C was more
TABLE 1.5 ANTIVIRAL SPECTRUM OF ARA-C
Nucleic acid 
DNA
RNA
Group
Poxvirus
Adenovirus
Herpesvirus
Papovavirus
Rhabdovirus
Virus
Smallpox
Vaccinia
Adenovirus
Herpes
Varicella-zoster 
Herpes marmoset 
Cytomegalovirus 
Herpes simiae 
Pseudorabies
SV40
Rabies
Vesicular stomatitis
Leukovirus Murine sarcoma
effective in fluid culture tests than IUdR, but only of equal efficacy 
in plaque suppression tests (Buthala, 1964; Rapp, 1964) (Table'1.6). 
However, the compound was more cytotoxic in tissue culture than IUdR 
(Buthala, 1964).
It was suggested by Goldenberg et al. (1968) that ara-C inhibits 
DNA synthesis in one of three ways, or a combination of these:
(a) by inhibition of the conversion of a ribonucleotide to a 
deoxyribonucleotide; (b) by incorporating into DNA, thus inhibiting 
synthesis; or (c) by phosphorylation to ara-CTP, which inhibits 
DNA polymerase.
Ara-C was found to be as effective in herpetic keratitis in man 
and animals as IUdR (Underwood, 1962; Kaufman and Maloney, 1963a). 
However, slight toxic effects were detected, for instance speckling of 
the cornea (Elliot and Schut, 1965), and this finding caused the 
discontinuation of ara-C in ophthalmic practice, even though the 
speckling disappeared on the termination of treatment.
Talley and Vaitkevicius (1963) noticed toxic side effects when 
ara-C was administered systemically, leading to such manifestations as 
leukopenia, anaemia and thrombocytopenia. Systemic treatment therefore 
was limited to 2 - 3  mg/kg/day, and was discontinued when signs of 
toxicity developed, for instance nausea and vomiting.
Any regime of systemic treatment with ara-C requires continuous 
infusion, as much of the ara-C is rapidly deaminated to uracil arabinoside 
which is inactive and excreted; that which is not deaminated remains 
to be phosphorylated to ara-CTP, which is the active antimetabolite.
Ara-C is now used systemically with many herpes virus infections with 
satisfactory results, as shown in Table 1.7 (Juel-Jensen and MacCallum, 
1972).
TABLE 1.6 COMPARISON OF ACTIVITIES OF IUdR AND ARA-C AGAINST 
HERPES VIRUS IN HEL CELLS BY MEANS OF THE 
PLAQUE SUPPRESSION TEST (Rapp, 1964)
Concn.
pg/ml
Compound
IUdR ara-C
PFU/ml % inhibition PFU/ml % inhibition
0.0 1.6 x 10® 0 8.3 x 107 0
0.1 - - 4.5 x 107 46.0
0.5 3.7 x 107 77.0 - -
1.0 5.8 x 106 96.4 <2.5 x 105 >99.7
10.0 2.3 x 105 99.9 <2.5 x 105 >99.7
TABLE 1.7 CLINICAL AND VIROLOGICAL RESULTS FROM SOME PATIENTS WITH 
SEVERE HERPES INFECTION TREATED WITH SYSTEMIC ARA-C 
(Juel-Jensen and MacCallum, 1972)
Sex Age Type Site
Response Duration of
virus isolation 
Clinical Virological (days)
M 22 1 Primary generalised Excellent Good 4
M 28 1 Primary generalised 
+ eczema herpeticum Excellent Good 5
M 27 1 Primary generalised Good Poor 20
M 19 Recurrent eczema 
herpeticum Excellent Excellent 3
F 64 1 Recurrent stomatitis Excellent Excellent 3
F 67 Recurrent stomatitis 
+ pneumonitis Excellent Excellent '■ 2 '
M 47 1 Recurrent stomatitis Excellent Good 4
M 56 Recurrent stomatitis Good Good 4
M 27 1 Primary stomatitis 
+ skin Excellent Good 5
M 20 Primary encephalitis Excellent (virus isolated 
from brain 
biopsy only)
F 19 2 Primary severe 
genital Excellent Good 5
F 24 2 Primary generalised Excellent Poor 12
Chow et al. (1970) and Hryniuk et al. (1972) found that lower dose
levels of 10 - 30 mg/m /day were most effective in a wide range of
herpes virus infections of varying degrees of clinical severity, without
significant toxicity to the host. They also reported success in the
treatment of disseminated varicella-zoster infections. Fortuny et al.
(1973) reported similar success against localised herpes zoster using 
o
a dose of 25 mg/m^/day, introduced intravenously for each of five 
succeeding days. The compound was apparently inactive against 
cytomegalic inclusion disease (McCracken and Luby, 1972; Kraybill et al.,
1972).
An important application of ara-C resulted from recognition of its 
activity against certain leukaemic conditions in man. Thus remission 
of symptoms of acute myeloblastic leukaemia (Bernard et al., 1966), 
acute and chronic lymphatic leukaemia (Howard et al., 1968), and leukaemic 
meningitis (Wang and Pratt, 1970) was obtained without undue signs of 
toxicity.
1.6.3 9-P-D-Arabinofuranosyladenine (Vidarabine, adenosine arabinoside, 
ara-A)
9-p-D-Arabinofuranosyladenine (ara-A) was first synthesized by 
Lee et al. (i960) as a potential anticancer agent, and although some 
activity against transplanted animal tumours was found, it is the more 
recently detected antiviral activity that has attracted more interest (Fig. 1.3) 
Ara-A was reported to be active against herpes virus and vaccinia virus 
in cell culture by Privat de Garilhe and de Rudder (1964). Subsequent 
work has shown that ara-A is active against a whole range of DNA viruses 
in tissue culture and the DNA-dependent RNA virus Rous sarcoma virus 
(Schabel, 1968; Miller et al., 1968). The antiviral spectrum is 
summarized in Table 1.8.
TABLE 1.8 ANTIVIRAL SPECTRUM OF ARA-A
Nucleic acid 
DNA
Group
Poxvirus
Herpesvirus
Virus
Vaccinia
Myxoma
Herpes
Varicella-zoster 
Herpes marmoset 
Cytomegalovirus 
Herpes simiae
Adenovirus Adenovirus 3
Ara-A is thought to act by blocking DNA synthesis, and was therefore 
produced as an antitumour compound, but no successful studies on its 
actual mode of antiviral action have yet been reported.
In vivo studies with ara-A against herpes virus infections have 
complemented the earlier reports on in vitro activity. Thus 
Sidwell et al. (1968) found that 5% ara-A in an ophthalmic base 
ointment containing 1% chloramphenicol given twice daily was very active 
against experimentally induced herpetic keratitis in hamsters. Not only 
was mortality reduced but survival times were increased, and there was 
a striking dose-response relationship. The therapeutic index (highest 
non-toxic dose/lowest effective dose) was greater than 60, compared with 
values of 2 and 4 for IUdR and ara-C under similar conditions.
Ara-A has also been found active against herpetic encephalitis, 
which may develop in hamsters infected with herpes virus (Schardein and 
Sidwell, 1968). Hamsters with ocular infections induced with herpes 
virus failed to produce encephalitis or show any evidence of virus after 
intraocular treatment twice daily with 10% ara-A in an ophthalmic base 
ointment. Untreated infected animals developed encephalitis and died 
between three to eleven days after inoculation.
Sloan et al. (1968) similarly found ara-A active against herpetic 
encephalitis in mice, when considerable reductions in virus titre were 
recorded and survival was prolonged. Subcutaneous, intraperitoneal or 
oral dosing with 400 mg/kg twice daily all proved to be comparable in 
results. Ara-A is rapidly deaminated in the body to ara-hypoxanthine, 
and Sloan compared the activity of the latter with that of ara-A, and 
it was found to be of almost equal activity to ara-A against herpetic 
encephalitis in mice when administered intraperitoneally (Table 1.9).
TABLE 1.9 COMPARISON OF THE ACTIVITY OF ARA-A AND ARA-HYPOXANTHINE 
IN MICE INFECTED INTRACEREBRALLY 24 HOURS PREVIOUSLY 
WITH 32 LD50 OF HERPES VIRUS (Schabel, 1968)
(Dosage 400 mg/kg/twice daily)
21 day survivors 
Survivors/total p value survivors
Mean survival
Mean death 
day
p value 
survivors
Untreated
controls
Ara-A
Ara-Hx
1/20
9/20
8/19
<0.05
<0.05
5.7
7.9
8.4
<0.001
<0.001
Although ara-A is accepted as an active antiviral agent, it is not 
yet recommended for the treatment of viral disease in man. It has, 
however, two advantages over ara-C which should ensure its future use 
in the treatment of herpetic infections: (a) it has a low toxicity and
may be used when patients suffer from bone marrow deficiency disorders; 
and (b) it is not an immunosuppressant.
1.6.4 5-Trifluoromethyl-2f-deoxyuridine (trifluorothymidine, TFT)
5-Trifluoromethyl-2’-deoxyuridine (TFT) was first synthesized 
by Heidelberger et al. (1962) following the interest at the time in 
fluorinated pyrimidines in connection with antitumour activity. Its 
structure resembles that of IUdR in that it is an analogue of the 
naturally occurring thymidine, the 5- position being substituted with 
a trifluoromethyl group, not iodine (Fig. 1.2).
The antitumour activity of TFT was shown in mice by Heidelberger 
and Anderson (1964), who found it to be equal in efficacy to FUdR against 
L1210 leukemia, less active than FUdR against sarcoma 180 and the 
Ehrlich ascites carcinoma, but more efficient than FUdR against 
adenocarcinoma 755. It was suggested at this time that the activity 
of TFT arose from the inhibition of thymidylate synthetase, which was 
substantiated by Reyes and Heidelberger (1965), who showed that TFT 
combined in an irreversible manner with thymidylate synthetase, thus 
inhibiting DNA replication. The DNA inhibitory properties of TFT led 
naturally to the possibility of antiviral activity, which was first 
demonstrated by Kaufman (1965), who found that TFT was more effective 
than IUdR and ara-C in the treatment of herpetic eye infections in 
rabbits. Activity was also shown against IUdR-resistant strains.
These results have since been confirmed by Hyndiuk et al. (1968) both in
tests in the rabbit eye as well as in tissue culture by plaque inhibition 
tests.
Sugar et al. (1973) later showed that TFT was effective by topical 
application in herpetic iritis, since it penetrated to the aqueous humour, 
a feature not shown by IUdR. Clinical evaluation has shown that 1% TFT 
significantly decreased the healing time of human herpetic infections 
when compared in a double-blind trial with 0.1% IUdR, the standard 
treatment for such infections (Wellings et al., 1972).
Work in tissue culture with vaccinia virus has gone some way to 
elucidating the mode of action of TFT. A comparison of IUdR, ara-C,
FUdR and TFT in HeLa cells has shown that the antiviral effect of 
ara-C and FUdR could be reversed on addition of thymidine 24 hours after 
infection with vaccinia virus, but this was not shown by TFT and IUdR; 
this suggested that they produced irreversible inhibition with selective 
toxicity for the virus (Umeda and Heidelberger, 1969). More recent work 
with vaccinia virus has shown that TFT inhibited only late mRNA, and 
studies of protein synthesis suggested that TFT prevented the induction 
of a major virus-induced protein (Oki and Heidelberger, 1971).
1.6.5 9-3-D-Arabinofuranosyl-2,6-diaminopurine hydrate (ara-DAP)
For many years purine and pyrimidine antimetabolites have been 
known to inhibit viral multiplication. The first purine antagonist 
shown to have antiviral activity was 2,6-diaminopurine. The 9-p-D- 
arabinofuranosyl derivative of adenine (ara-A) has been shown to be 
active against herpes and vaccinia viruses. This compound, however, 
is rapidly deaminated to the hypoxanthine analogue, a compound of 
lower potency (Brink and LePage, 1964a, b). It is suggested that 
2,6-diaminopurine nucleotides are deaminated by adenosine deaminase
less rapidly than ara-A (Rockwell and Maguire, 1966). Therefore the 
9-3-D-arabinofuranosyl derivative of 2,6-diaminopurine was synthesized 
and it was hoped that this compound (ara-DAP) would possess a longer 
half-life in vivo than that of ara-A (Fig. 1.3).
The antiviral activity of ara-DAP was first demonstrated in mice 
which were infected intracerebrally with vaccinia virus and treated 
subcutaneously with the compound. Substantial activity was shown by 
this technique, with doses of 1.25-50 mg/kg twice daily. Activity 
has similarly been shown against herpes virus types 1 and 2. Results 
with experimentally induced herpetic and vaccinial keratitis in rabbits 
confirm the work in mice. Activity has also been shown against 
adenoviruses, but not against any RNA viruses (Elion et al., 1975).
1.7 DIFFERENTIAL SUSCEPTIBILITY OF HERPES VIRUS TYPES 1 AND 2
All the compounds discussed are quite closely related in that they 
are substituted purines (ara-A and ara-DAP) or substituted pyrimidines 
(IUdR, ara-C and TFT), and they all have similar sugar moieties, 
arabinose or deoxyribose. There have been numerous reports of differences 
in activities of these compounds against type 1 and 2 herpes viruses.
Type 1 strains have been reported to be more sensitive than type 2 strains. 
The first references to such a difference were made by Alford (1987) and 
Nahmias and Dowdle (1968), but neither gave any experimental evidence 
for their statements.
The first experimental results which showed a difference in 
sensitivity were those of Lowry and Rawls (1969), who assayed the 
sensitivities of type 1 and type 2 strains against IUdR and ara-A in 
rabbit kidney cells. Both compounds were found to be more active against
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type 1 strains. These results were substantiated when Person et al. (1970) 
studied the sensitivities of strains to IUdR and ara-A by comparing 
dose-response lines obtained from plaque inhibition studies in chick 
embryo fibroblasts, WI-38 and HeLa cells. Type 2 strains were found 
to be less sensitive than type 1 strains to IUdR in chick fibroblasts 
and 1/1-38 cells but not in HeLa cells. Similar but less marked 
differences were observed with ara-A. The extent of the differences 
in sensitivity varied between the cell lines used, the greatest being 
shown in chick fibroblasts, and little difference was observed with 
ara-A in HeLa cells.
Using 3 type 1 and 2 type 2 strains, Walker et al. (1970) found 
similar differences in susceptibility with IUdR in rabbit kidney, WI-38 
and HeLa cells, although all strains showed almost identical sensitivity 
to ara-C. Zones of inhibition were obtained with IUdR (1000 pg/ml) and 
ara-A (500 pg/ml) in plaque inhibition tests in chick fibroblasts, and 
the resultant diameters with type 1 and type 2 strains were compared 
(Lowry et al., 1971). The large plaque-forming type 2 strains produced 
smaller zones than the smaller plaque-forming type 1 strains when tested 
against IUdR, but no differences were observed with ara-A.
From studies in WI-38 cells Fiala et al. (1972a, b) determined 
minimum inhibitory concentrations (MIC) for ara-C of 0.25 - 0.75 pg/ml 
for 7 type 1 strains, and 0.37 - 2.0 jig/ml for 9 type 2 strains. The 
same workers (Fiala et al., 1974) found similar differences in MIC values 
for ara-A (type 1, 8 - 12 pg/ml; type 2, 12 - 24 jig/ml); with IUdR the 
mean values showed that type 1 strains were more sensitive than type 2 
strains, but the ranges showed considerable overlap (type 1, 37 - 75 pg/ml; 
type 2, 25 - 75 pg/ml). The results for ara-C were substantiated by 
Nutter and Rapp (1973), who used human embryonic kidney and primary 
rabbit kidney cells.
The most comprehensive study of differential type sensitivity was 
that of Jones et al. (1973), who tested the sensitivities of IUdR, ara-C, 
ara-A and ara-Hx in primary hamster kidney and primary rabbit kidney cells 
against 10 type 1 and 11 type 2 isolates and made a comparison of the 
MIC values. They concluded from their studies that there were ranges 
of sensitivities of the strains to the compounds and that there was a 
great deal of overlap between types. IUdR and ara-C were found the 
most active against type 1 strains, but only ara-C maintained high 
activity against type 2 strains. Ara-A and ara-Hx, although similarly 
active against both types, were less so than IUdR and ara-C. Finally 
they concluded that type 1 and type 2 could not be reliably distinguished 
by _in vitro drug sensitivity patterns.
One final point relating to the sensitivity of herpes virus types 
was made by Hutton et al. (1972), who showed that type 2 strains were 
more sensitive than type 1 strains to inhibition by the sulphated 
polyanions dextran sulphate, hyaluronic acid and agar inhibition 
substance (DIFCO).
1.8 AIMS
From an examination of the literature on the chemotherapy of herpes 
virus infections it appears that there are two aspects which have been 
insufficiently studied. Firstly, there has been no simultaneous comparison 
in the same test system of those compounds which are in clinical use, so 
that there is a lack of definite information on their relative potencies.
Also, there is insufficient information available on the differential 
sensitivity of strains belonging to the two different types of herpes virus, 
although the consensus of opinion at the present time is that type 2 strains
are less sensitive than those of type 1.
The aim of the present work was therefore to evaluate different 
methods of detecting and quantitating antiviral activity against herpes 
and, having selected the most suitable method, to apply it to an investigation 
of the above two problems.
MATERIALS AND METHODS
2.1 INTRODUCTION 
2*1.1 Egg systems
The ability of herpes virus to grow and produce pocks on the 
chorioallantoic membrane (CAM) of embryonated hens' eggs has been known for 
many years (Goodpasture et al., 1931; Saddington, 1932; Dawson, 1933; 
Burnet et al., 1939; Burnet and Lush, 1939a, b; Shaffer and Enders, 1939; 
Anderson, 1940). Growth has also been recorded in the amniotic cavity 
and in the brains of 13 day old embryos (Anderson, 1940), but the growth 
and the production of pocks on the membrane is a feature that has 
recently been successfully utilised for the differentiation of oral and 
genital strains of human herpes virus, the genital or type 2 strains 
producing characteristically larger pocks than the oral, type 1 strains 
(Nahmias et al•, 1968). The technique is now a well established one 
because of its reliability and reproducibility, and was selected as the 
primary method of typing the strains of herpes virus used in the 
present study.
2.1.2 Animal systems
The animals, mice and rabbits, used in this study are species 
used routinely in these laboratories, the Wellcome Research Laboratories, 
for screening potential antiherpes compounds. Intracerebral inoculation 
of mice was found to be a most satisfactory method of demonstrating the 
pathogenicity of herpes virus infection, producing encephalitis and 
death (Andervont, 1929). Infected animals were easily subjected to 
systemic chemical treatment by the oral or parenteral routes. Increased 
survival times give not only a measure of antiviral activity, but also a
preliminary indication of the survival of the drug on systemic 
treatment.
The rabbit has served for the cultivation of herpes virus for 
many years, in fact herpes virus was first cultivated in the rabbit eye 
in 1914 (Gruter, 1924; Lipschutz, 1921, 1932). Since this early work 
the production of specific herpetic keratitis in the rabbit eye has 
become more sophisticated, with the controlled scarification and inoculation 
of the corneal epithelium resulting in an established infection 1 - 3  days 
later. Such an infection is an ideal model for the topical treatment of 
keratitis because of the avascular nature of the cells of the cornea.
This method therefore gives both a qualitative measure of antiviral 
activity as well as an indication of the toxicity of the test compound 
on topical administration. The technique is also important because the 
infection induced is clinically similar to the herpes virus keratitis 
found in man, which may be severe and threaten sight.
2.1.3 Tissue culture systems
The assay of virus in cells grown in glass was first performed by 
Morann and Melnick (1953), who titrated poliomyelitis virus in monkey 
kidney tissue grown on glass. The cells originated from an organ 
culture which, unlike the practice then in use, was not grown in plasma 
clot, but simply grew out from the organ culture at the glass surface.
The assay of the infectivity of herpes virus in tube cultures was first 
developed by Barski et al. (1955) and Sosa-Martinez ot al. (1955) in 
rabbit kidney tissue, and these methods, as well as certain modifications 
of them, have since been used to assay antiviral activity by measuring 
reductions in infectivity.
A modification of the tube test is that of the microtitre assay,
where the virus and cells are allowed to settle out simultaneously in 
the flat bottomed wells of a microtitre plate (Sidwell and Huffman, 1971); 
there the progressive cytopathic effect can be more readily observed 
than in tubes.
The plaque assay system was an important refinement of cell culture
I
technology, and was first described by Dulbecco (1952) and Di^ Jbecco and 
Vogt (1954), who produced plaques with all three types of polio virus 
in monolayers of monkey kidney and monkey testis tissue under a solid 
overlay. Plaque numbers were found to vary in direct proportion to 
virus dilution, and this linear response led to the inference that 
each plaque was initiated by a single infectious particle. Following 
the early reports of Bickerstaff (1953) of the nature of the 
cytopathic effect of herpes virus in chick embryo fibroblasts, it was 
found that herpes virus also produced plaques under solid overlay in 
chick cells (Waterson, 1958), in rabbit kidney cells (Farnham, 1958; 
Wheeler, 1958), and in HeLa cells fyantsis and Wildy, 1962), the same 
proportionality between plaque number and virus dilution was found 
throughout these studies.
An alternative method for the inhibition of plaque formation was 
by the incorporation of the test compound into filter paper discs which 
were placed on the centre of the solid overlay of an infected culture 
(Herrmann et al •, 1960; Rada et al., 1960). In this method the diffusion 
of the drug through the overlay inhibited the replication of the virus 
thus preventing plaque formation.
The gradient plate plaque reduction technique was basically a 
refinement of the two plaque techniques previously described, and was 
first described by Kucera and Herrmann (1966) for the assay of antiviral 
agents, although the technique was first developed for bacteriological
work (Szybalski, 1952). This technique depends on a gradient of solid 
overlay containing the test compound which is allowed to diffuse through 
a wedge of control medium. By this technique the active range of a 
compound may be demonstrated in a culture, as the infected cells are 
exposed to a gradient of concentrations of the test compound.
2.2 SELECTION AND CULTIVATION OF STRAINS OF VIRUS
This study was performed with type 1 and type 2 strains of 
herpes virus listed in Table 2.1. After the strains had been typed 
(2.2.1) they were given the serial numbers 1 - 12 and 20 —  31 as shown 
in Table 2.1. A gap was left between 12 and 20 to accommodate any 
further strains which might have become available.
Seed stocks of each virus were prepared in embryonated eggs from 
specific pathogen free White Leghorn eggs tested for absence of leukosis 
group viruses, infectious bronchitis, infectious laryngotracheitis, 
Newcastle disease virus, Marek's disease virus, avian encephalomyelitis 
virus, reticuloendotheliosis virus, poxviruses, infectious bursal disease 
virus, Mycoplasma gallisepticum and Salmonella spp. pathogenic for 
chickens (Joyce Hill Ltd., Norfolk). Virus was inoculated onto the 
chorioallantoic membrane (CAM) at the thirteenth day of incubation, and 
after further incubation of the eggs at 35 - 36°C for 3 days the membranes 
were harvested. Membranes exhibiting confluent areas of characteristic 
pocks were aseptically removed and ground to a fine paste with sterile 
sand in a pestle and mortar. The homogenate was resuspended in medium 
consisting of 1% foetal calf serum (Flow Laboratories Ltd., Irvine, 
Scotland), 10% Eagle minimal essential medium, 25% of a 4.4% solution 
of sodium bicarbonate and 0.25% Crystamycin (Glaxo Laboratories Ltd.,
TABLE 2.1 SOURCES OF STRAINS OF HERPES VIRUS USED IN THIS WORK
Original code Source whenSreceired Owncode
HI Nose swab 2 1 1
H7 Throat swab 2 1 2
H14 Throat swab 2 1 3
H15 Throat swab 2 1 4
H29 Lip lesion 2 1 5
H31 Throat swab 2 1 6
H38 Leg lesion 2 1 7
H44 Throat swab 2 1 8
H64 Throat swab 2 1 9
H71 Throat swab 2 1 10
ICI Unknown Unknown 1 11
HFEM Oral Multiple egg T/C 1 12
mouse
IF Cervical swab 2 2 20
2F ** 2 2 21
3F " 4 2 22
4F tt 2 2 23
5F 11 1 2 24
6F " 2 2 25
7F " 1 2 26
8F M 1 2 27
9F 11 1 2 28
10F 11 1 2 29
11F ” 1 2 30
PAR '* 1 2 31
Middlesex), one ml of which was used for every membrane ground. The 
debris and sand were then removed by low speed centrifugation (2000 rpra 
for 4 minutes at room temperature). The supernatant formed a crude 
virus suspension which was dispensed into 1 ml aliquots and was stored 
at -70°C.
2.2.1 Subdivision of herpes virus strains
Differentiation of the virus type was done on the basis of 
pock morphology. Serial tenfold dilutions of the stock cultures were 
prepared and 0.1 ml volumes of each dilution were inoculated on to the 
chorioallantoic membranes of 13 day old eggs. After incubation for 
three days the membranes were removed and those showing a good spread 
of countable pocks were photographed in order to prepare slides, on the 
basis of which pock diameters were measured. Slides incorporating a 
10 mm scale were projected, and using a pair of dividers three 
measurements of each pock were recorded and the mean calculated. About 
twenty pocks were measured for each strain of virus and the distribution 
of the sizes were displayed by means of a histogram. This enabled a 
complete comparison of the ranges of pock diameters recorded to be made 
and two distinct virus types to be differentiated.
These results were confirmed by the characteristic features that 
herpes virus strains produce on infection of VERO cells in culture 
(plaque size and the nature of cytopathic effect).
2.3 SOURCES OF COMPOUNDS
The compounds used in this work were obtained from the following 
sources :
5-Iodo-2'-deoxyuridine (XUdR) was purchased from Koch-Light Laboratories, 
Colnbrook, Bucks.
1-p-D-Arabinofuranosylcytosine (ara-C) was purchased from Koch-Light 
Laboratories, Colnbrook, Bucks.
9-p-D-Arabinofuranosyladenine (ara-A) was a gift from Dr. E.F. Elslager, 
Parke-Davis and Co., Ann Arbor, Michigan 48106, U.S.A.
5-Trifluororaethyl-2'-deoxyuridine (TFT) was purchased from Heinrich Mack 
Nachf., Mannheim, German Federal Republic.
9-p-D-Arabinofuranosyl-2,6-diaminopurine hydrate (ara-DAP) was supplied 
by Dr. G.B. Elion, Burroughs Wellcome Inc., Research Triangle Park,
North Carolina 27709, U.S.A.
2.4 ASSAY OF ANTIVIRAL ACTIVITY IN ANIMALS
2.4.1 Studies in mice
Studies in mice required the adaptation of the viruses to mouse
tissue and the consequent preparation of suitable stock cultures of virus.
Swiss mice (Scientific Animal Supplies, Aylesbury, Bucks.) weighing
between 12 - 15 grammes were selected, and were anaesthetised with ether
and inoculated intracerebrally with 0.025 ml of seed stock virus. The
mice were examined daily for the appearance of symptoms typical of herpes
encephalitis, i.e. cerebral irritation which leads to paralysis, coma and
ultimately death. Mice were killed when they showed the early symptoms
of cerebral irritation, when the virus was known to be present in maximum
titre. The viscera of the mice were examined for signs of infection with
bacteria or other agents, and if no abnormalities were found the brains
were removed aseptically and ground to a smooth paste in a pestle and mortar.
The homogenate was resuspended in the maintenance medium described above,
mixed with glycerol in the ratio 2:1, and 4 ml of the medium was used for
every brain ground (each brain weighing approximately 400 mg). This
-1preparation was therefore at a dilution of 10 and was stored at -20°C.
Fresh stocks of brain homogenate were prepared every three months 
because there was some evidence for loss of virus titre on storage.
The stocks of virus thus prepared were titrated in mice. Serial 
tenfold dilutions of the mouse adapted strain of virus were prepared in 
phosphate buffered saline (PBS) and stored in bijou bottles held on 
crushed ice to reduce thermal inactivation of the virus. The virus 
was then inoculated intracerebrally into groups of 10 mice which were 
subsequently examined twice daily (at 9.00 a.m. and 6.00 p.m.) for signs 
of infection. The survival times of the mice were recorded to the 
nearest half day, and these values were converted to reciprocals. These
values were plotted against the log of the virus dilution to demonstrate 
linear response (Gard, 1940).
Virus titres from the survival times of animals were derived by 
means of the Karber equation, where :
loglO ID50 = m - A (Jp - J) (Karber, 1931)
where m = log of the virus dilution corresponding to the largest
proportion (i.e. the lowest dilution from which p is calculated) 
p = the proportion of infected animals (i.e. proportion of deaths 
to survivals)
X p = the sum of the proportions for the dilutions from m to the 
highest dilution at which deaths were recorded 
A = the constant dilution interval
serial tenfold A = 1
serial hundredfold A = 2
Knowing the infectivity of the virus, preliminary experiments were 
performed initially to detect antiviral activity of the compounds under 
test. Standardised assays were done by inoculating groups of 5 mice 
with virus at approximately 100 LD50. Subcutaneous treatment was 
started 2 - 3  hours later at a standard concentration of 5 mg/ml in 
water, and continued for 4^ days. Survival times of the mice were 
recorded as before, and compounds that showed any significant increases 
in survival times compared to those of virus control groups indicated 
activity. The activity of such compounds were then more fully studied 
by comparing dose-response lines of treated and untreated animals. Groups 
of ten mice were inoculated intracerebrally, one group with 1 LD50 and
the other with 100 LD50, five mice from each group being retained as 
virus controls. The remaining mice were treated as before for 4J days, 
and survival times were recorded over a 14 day period (Bauer, 1958).
The results were then converted to reciprocal survival times and plotted 
against the log of the virus dilution for both test and control groups. 
Generally the two lines run parallel and the horizontal distance between 
them can be calculated as the statistical estimation of the activity of 
the compound (relative potency).
2.4.2 Studies in rabbits
These were done on 5 lb male New Zealand white animals (Ranch
Rabbits, Sussex), and the eye was chosen as the model site because of
the importance of ocular infections in man.
The method of inoculation of the eye was closely aligned to that
described by Jones et al. (1968), who described a standardised technique 
for the assay of virus replication in the cornea. The rabbit was 
given light general anaesthesia with intravenous Veterinary Nembutal 
(Abbott Laboratories, Queenborough, Kent), with 0.2 mg/lb body weight, 
and full local anaesthesia was obtained with drops of amethocaine 
hydrochloride 1% w/v (Evans Medical, Speke, Liverpool), or by retrobulbar 
injection of 0.5 ml 1% lignocaine hydrochloride (Versicaine, May and 
Baker Ltd., Dagenham). The eye was then proptosed and clamped with a 
tenaculum to prevent its return, and the inoculum was introduced with 
the aid of a glass capillary tube (trephine). The trephines were 
examined microscopically before use and only those where the terminal 
annulus was free from cracks and jagged edges were selected. A suitable 
trephine was filled with virus suspension by capillary action, and was 
then plugged with plasticine to prevent its escape. The plug also
prevented uptake of lacrimal fluid from the eye which would result in 
dilution of the inoculum and prevent the administration of a standard 
dose. The external surface of the tube was then blotted dry with a 
sterile filter paper and the inoculation procedure was monitored under 
the 10X objective of an operating microscope (Carl Zeiss, Oberkochen,
Vest Germany)• The trephine was placed on the chosen site on the cornea 
at right angles to the surface, and was rotated under gentle pressure 
sufficient to cut through the epithelium to the stromal surface (Fig. 2.1). 
Before the trephine was removed excess fluid around the tip was soaked up 
with sterile filter paper. The trephine was then removed and excess 
fluid left in the centre of the circular cut was also soaked up, thus 
leaving the inoculum restricted to the cut. Sixteen such inoculations 
were made in each eye arranged in the form of a diagonally drawn cross.
Each arm of the cross contained four replicate inoculations of a virus 
dilution, and a central well was cut to act as a control serving to show 
whether there was any spread of virus from one inoculation site to 
another (Fig. 2.2).
This number of inoculations, however, was only used to titrate 
virus stocks; for antiviral activity assays a cross of only eight 
inoculation sites was made, all with the same virus dilution, and again 
with the central control.
Both eyes of a rabbit were inoculated in the same manner; one was 
used as the untreated virus control and the other received the designated 
treatment. The infection was allowed to become established over a 
72 hour period. The eyes were examined daily to determine the extent 
of infection, and lesions on the corneal surface were detected by staining 
with 1% Bengal Rose or 1% fluorescein. The extent of infection was 
given a numerical score for such features as opacity of the cornea,
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Fig. 2.1 Diagrammatic representation of the procedure 
for the inoculation of the rabbit eye
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Fig. 2.2 The position of inoculation sites on the cornea
oedema of the conjunctiva, and the amount of discharge from the eye.
This scoring system was first described by Corwin et al. (1963), and is 
illustrated in Table 2.2. The eye showing the most extensive infection 
was selected as the test eye and the other as the untreated control.
The eyes were examined daily throughout treatment, and results were 
recorded with the aid of a drawing on record sheets of the extent of 
corneal involvement (Fig. 2.3), as well as entering the score of the 
features (Fig. 2.4).
Compounds under test were administered in the form of 0.1 ml drops 
five times each day (at 9.00 a.m., 11.00 a.m., 1.00 p.m.,3.00 p.m. and
5.00 p.m.) over a five day period. The selected drug concentrations 
were between 0.5% and 0.1%, and the diluent was 0.01# benzalkonium 
chloride (Koch-Light Laboratories Ltd., Bucks, England), which acts as 
a bacteriostatic agent to reduce the level of secondary infection of 
the conjunctiva.
2.5 ASSAY OF ANTIVIRAL ACTIVITY IN CELL CULTURE
2.5.1 Choice and standardisation of cultures
Three cell lines were used: VERO, HEp.2 and HEL, of which
VERO cells were used predominantly because of their suitability for 
the production of plaques.
VERO cells, a continuous cell line derived from the kidneys of a 
normal adult African green monkey (C. aethiops), (Yasamura and 
Kawakita, 1963) were obtained from Flow Laboratories, Irvine, Scotland, 
who in turn obtained them less than 25 generations old from the 
American Type Culture Collection.
HEp.2 cells, a human epidermoid cell line obtained from tumours
TABLE 2.2 SCALE OF WEIGHTED SCORES FOR GRADING THE SEVERITY OF OCULAR LESIONS
(Corwin et al., 1963)
I. Cornea
A. Opacity, degree of density (area which is most dense is
taken for reading)
Scattered or diffuse area, details of iris clearly visible 1
Easily discernible translucent areas, details of iris
slightly obscured 2
Opalescent areas, no details of iris visible, size of 
pupil barely discernible 
Opaque, iris invisible
B. Area of cornea involved
One quarter (or less) but not zero 
Greater than one quarter, less than one half 
Greater than one half, less than three quarters 
Greater than thfee quarters up to whole area
Score equals (A + B) x 10 total maximum = 80
II. Conjunctiva
A. Redness (refers to palpebral conjunctivas only)
Vessels definitely injected above normal 
More diffuse, deeper crimson red, individual vessels 
not easily discernible 
Diffuse beefy red
B. Cheraosis
Any swelling above normal (includes nictitating membrane)
Obvious swelling with partial eversion of the lids 
Swelling with lids about half closed
Swelling with lids about half closed to completely closed
C. Discharge
Any amount different from normal (does not include small
amount observed in inner canthus of normal animals) 1
Discharge with moistening of the lids and hairs just
adjacent to the lids 2
Discharge with moistening of the lids and considerable
area around the eye 3
Score (A + B + C) x 2 total maximum =20
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2.5.2 Cell counting
For all assay techniques cells were seeded at a known concentration. 
Pellets of cells were suspended in 10 ml of growth medium and 0.1 ml of 
this was then mixed with 0.1 ml of 0.5% aqueous trypan blue (British Drug 
Houses, Poole, England). The stained cells were then counted in a 
Neubauer counting chamber (Hawksley and Sons Ltd., Lancing, England).
2.5.3 Preparation of stock cultures of virus in cell culture
For all tests in tissue culture stocks of virus were prepared in 
confluent cultures of VERO cells grown in 200 ml Pyrex centrifuge bottles. 
These bottles were seeded with 25 ml of a cell suspension at the 
concentration used for stock subculture, and were incubated at 37°C 
until a confluent monolayer was attained,(l - 2 days). The medium 
was then removed and the cells infected with 5 ml of a suspension of 
seed virus containing 10 pfu/ml in maintenance medium. The bottles 
were then rolled at 35°C for one hour to allow the virus to adsorb, and 
then the fluid was removed and replaced with 25 ml of fresh maintenance 
medium. The culture was again rolled at 35°C for approximately 48 hours, 
by which time the virus had caused maximum cytopathic effect, and the 
virus was harvested by the following procedure. The bottles were 
removed and subjected to three successive cycles of freezing and thawing 
(-70°C : room temperature). The resultant suspension (25 ml) was 
sonicated in an Electrosonic H120 Sonicator bath (Electrosonic Headland, 
London) for two minutes to disrupt the cells further and thereby ensure 
a complete release of virus particles. The cell debris was deposited 
by low speed centrifugation (2000 g for 2 minutes at room temperature), 
and the supernatant was dispensed in one ml aliquots which were stored 
at -70°C.
developed in irradiated-cortisonised weanling rats after infection with 
epidermoid carcinoma tissue from the larynx of a 56 year old male 
(Toolan, 1954; Moore et al., 1955), were also obtained from Flow 
Laboratories. They were from the American Type Culture Collection 
and were less than 25 generations old.
HEL cells were a continuous fibroblastic cell line prepared by 
the Tissue Culture Department, Wellcome Research Laboratories, from a 
human embryo lung. The cell line is routinely maintained by that 
department, and cultures were provided when required.
These cell lines were all used in various techniques which will 
be described, including the preparation of stock cultures of virus and 
for the assay of antiviral activity.
Stock cultures of VERO and HEp.2 cells were grown in 12 oz. medical 
flat bottles in 10% Eagle minimal essential medium (Wellcome Reagents Ltd.), 
containing 5% foetal calf serum (Flow Laboratories) for VERO cells and 
10% foetal calf serum for HEp.2 cells, and 0.11% sodium bicarbonate 
solution (Wellcome Reagents Ltd.) with 0.25% Crystaraycin, 50 000 units/ml 
sodium benzyl penicillin BP and 50 mg/ml streptomycin sulphate BP 
(Glaxo Laboratories, Greenford, England).
The cultures were subcultured every fourth day into five (VERO) 
and four (HEp.2) new 12 oz. bottles. For the preparation of stocks of 
virus and for tests of inhibitory chemicals, various different vessels 
were used and the fully grown cultures were maintained on a medium 
prepared like growth medium but with the serum concentration reduced 
to 1%.
Stock cultures of HEL cells were grown in 4 oz. medical flat bottles 
in 10% Eagle basal medium with 10% foetal calf serum but otherwise the 
same as that for VERO and HEp.2 cells.
2.5*4 Preparation of drug stocks
In all cases drugs were prepared in aqueous solutions. For all 
techniques except plaque inhibition drug dilutions were prepared from 
1 mM stock solutions maintained at 4°C. Plaque inhibition, on the 
other hand, utilised aqueous solutions of 5 mg/ml of each compound. 
Solubility problems, when they arose, were overcome by gentle heating 
of the mixture.
2.5.5 Infectivity titrations
The tube and microtitre plate titration methods were both 
adopted, although on different occasions, to demonstrate antiviral 
activity by the reduction of the infectivity endpoint of the virus 
in infected tissue culture.
For the tube test 1 ml volumes of a suspension of VERO cells 
5(l x 10 cells/ml) were pipetted into 6" x Pyrex glass tubes which 
were then sealed with rubber bungs. The tubes were incubated at a 
slight slope at 37°C for approximately 24 hours when confluent monolayers 
were formed. The tubes were then drained and infected with 0.25 ml 
volumes of perial tenfold dilutions of stock virus suspension in 
maintenance medium, and rolled at a speed of 10 revolutions/hour on a 
Matburn roller apparatus (Baird and Tatlock Ltd., Chadwell Heath,
Essex, England) for one hour at 37°C to allow for virus adsorption.
The fluid was then removed and the cells were washed with 2 ml of 
maintenance medium before being fed with a final 2 ml volume of maintenance 
medium. For tests of chemical inhibitors a parallel set of infected 
cultures were prepared in the same way but were fed with maintenance 
medium containing a known dilution of the test compound. The inoculated 
cultures were then incubated at 37°C on a roller apparatus, and were
examined twice daily. The extent of cytopathic effect was observed and 
recorded as follows :
0 none
1 less than 25%
2 greater than 25% but less than 50%
3 greater than 50% but less than 75%
4 greater than 75%
Many fields were examined before a conclusion on the extent of 
cytopathic effect was recorded.
When 50% CPE was reached this time was recorded and converted 
into reciprocal survival time to be later plotted against the log of 
the virus dose. The dose-response lines obtained in this way for a 
test compound were compared with untreated control cultures. The 
horizontal distance between the control line and that for the test 
compound was a measure of the activity of the compound (relative potency, 
as in the mouse experiments). A more accurate measure of activity in 
tube cultures was found when CPE could first be detected in both treated 
and control cultures. The difference in hours between these times in 
treated and control cultures was then taken as the delay in appearance 
of CPE, and was plotted against the virus concentration.
The microtitre plate method differed only quantitatively. The 
flat bottomed wells of a microtitre plate (Falcon Plastics, Oxnard,
Ca. 93030, U.S.A.) were seeded with 0.075 ml of VERO cell suspension
5
(l x 10 cells/ml) using 0.025 ml droppers (Biocult Laboratories Ltd., 
Paisley, Scotland), and 0.025 ml of dilutions of virus suspension were 
added to 6 replicate wells. To half of the infected cultures
0.025 ml of test compound was added, and to the control virus titration 
wells 1 drop (0.025 ml) of maintenance medium was added. The plates 
were then sealed with adhesive covers and incubated at 37°C for 
48 - 72 hours. The cultures were examined daily for the first 
appearance of cytopathic effect, and this time was recorded for both 
treated and control cultures.
2.5.6 Plaque assay techniques
Three complementary plaque techniques were adopted: plaque
reduction, plaque inhibition and gradient plates. The technique of 
plaque assay was also used to titrate virus yields. VERO cells were 
used for all techniques involving plaques.
To titrate virus samples 60 mm x 15 mm tissue culture dishes 
(Falcon Plastics, U.S.A.) were seeded with 8 ml of VERO cell suspension 
(l x 10 cells/ml) to establish a confluent monolayer overnight, the 
plates being incubated at 37°C in an atmosphere of 5% CO^. The confluent 
monolayers were infected with 2 ml volumes of serial tenfold dilutions 
of virus in maintenance medium. Such large volumes of inoculum were 
used in order to obtain uniform distribution of plaques, since smaller 
volumes tended to give rise to plaques orientated around the edges of 
the plates. After adsorption for 1 hour at 37°C the inoculum was 
removed and the plates were carefully drained. An overlay medium at 
42°C, consisting of 0.6% agarose (Indubiose A37, 92 Gennevilliers, France) 
dissolved in maintenance medium, was dispensed to the plates in volumes 
of 8 ml. The plates were re-incubated at 37°C in 5% CO^ in air for 
96 hours to allow the formation of plaques. The cultures were fixed 
by the addition of 3 ml of 10% formalin solution in phosphate buffered 
saline per plate, and after one hour the agarose layer was removed and
the cells washed with distilled water. The plaques were made visible 
by staining the cell sheet with 2 ml of 0*5% methyl violet in 20% methanol 
which stained the cells blue to violet, leaving the plaques as clear 
unstained areas in the cell sheet. The plaques were counted and the 
result was expressed as plaque-forming units per ml of virus suspension 
(pfu/ml), and was taken to be the titre of the virus based on the 
assumption that one virus particle initiated the formation of one plaque.
2.5.7 Plaque inhibition
For this variant of the plaque test monolayers of VERO cells were
prepared as usual except that 100 x 20 mm tissue culture dishes (Falcon
Plastics) were used and were seeded with 18 ml of a cell suspension 
5containing 1 x 10 cells/ml. The cultures were incubated in the same 
manner as in the other plaque techniques. The confluent monolayers 
were drained of medium and infected with 5 ml of a suspension of virus 
containing sufficient virus to produce a confluent spread of plaques 
throughout the monolayer. After infection the cultures were allowed 
to adsorb the virus for 1 hour before the inoculum was removed and the 
plates overlayed with 18 ml of agarose overlay. Sterile filter paper 
discs impregnated with the test compound were then placed at the centre 
of each culture. These discs were 6 mm in diameter and were punched 
from sheets of 3 MM filter paper (Whatman). They were sterilised by 
heating in an oven at 150°C for 2 hours. The cultures were incubated 
for 96 hours at 37°C, when the monolayers were examined for plaque 
inhibition. The edge of the zone of plaque inhibition was taken to 
be that where no plaques developed, not the area where plaques were 
visible but their number and size affected. The average of four 
measurements of such a zone was taken as the actual zone diameter, and
these values obtained for each test compound were compared. All compounds 
were tested at a concentration of 5 mg/ml in water, i.e. 50 jig/disc.
Any compound toxicity was also demonstrated by this technique when a 
zone of cell death was observed.
2.5.8 Plaque reduction
Monolayer cultures of VERO cells were prepared as described above.
On the basis of the plaque count a dilution for each virus was selected 
which provided sufficient virus to induce the production of a reasonable 
count of plaques per plate (between 200 and 400). For the test a series 
of replicate plates were overlayed, after inoculation as above, with 
medium containing doubling dilutions of the test compound. The plates 
were incubated as before, and the plaques produced were examined and 
counted in order to obtain comparative data. The result of the test 
plate count was expressed as a percentage of the virus control and 
plotted against the log of the compound concentration, from which slopes 
and relative potencies were compared. The dose-response lines were also 
extrapolated back to give a comparison of the minima inhibitory 
concentrations of the test compounds, that is the lowest amount of 
compound required to prevent viral replication.
2.5.9 Gradient plate plaque reduction
2
Tissue culture flasks 25 cm (Falcon Plastics) were seeded with
5
8 ml of a VERO cell suspension (lx 10 cells/ml) and were incubated 
at 37°C overnight to grow to confluency. The monolayers were then 
infected with 2 ml volumes of virus suspension in maintenance medium.
Again the selected virus concentration was that producing a confluent 
spread of plaques (between 200 and 400 per flask). After adsorption
for one hour the virus was aspirated and the flasks well drained. It
was important to ensure that the flasks were fully drained so that the
primary overlay adhered completely to the flask surface, otherwise
on the addition of the second overlay (see later) the first overlay
lifted and the gradient effect was lost. Volumes of 5 ml of maintenance
medium overlay at 41°C were added to each flask, which was angled along
the long axis to produce a wedge of overlay, the thinnest edge of agarose
being at the top of the flask. This primary overlay was allowed to
solidify at room temperature before a second overlay of 5 ml of
maintenance medium with a known concentration of test compound was
carefully added. The flasks were then placed in a horizontal position
to allow the overlay to solidify thus producing a second wedge of overlay,
this time containing drug (Fig. 2.5). The flasks were incubated at 37°C
for 96 hours, and the cells were fixed and stained as previously described.
The function of the double wedge of agarose was to produce a regular
gradient of drug concentration to act against the virus and produce a
gradation in the number of plaques which developed. The part where
plaques were no longer found was equivalent to the minimum inhibitory
concentration of the compound, and the concentration of the compound at
this point was then determined. It was proportional to the ratio of
dlthe thickness of the two wedges, where C„ = sC x C (Fig. 2.5).1 'd2 max °
These minimal inhibitory concentrations may then be compared in order 
to determine the relative activities of the test compounds.
2.5.10 Yield reduction
Virus growth cycles were standardised to establish the generation 
time of the viruses used. VERO cells were grown to confluency overnight 
as for the gradient plate plaque reduction method, and infected with
medium + drugnormal medium
max,•min.
*
position of complete 
plaque suppression
max
Fig. 2 .5  • D iagram m atic representation o f gradient plate
plaque reduction
1 ml of virus at a multiplicity of one virus particle per cell*
After virus adsorption for one hour at 37°C, the flasks were washed 
twice with 5 ml of maintenance medium, before being fed with 8 ml of 
maintenance medium. The flasks were then incubated at 37°C for a 
further 24 hours, duplicate samples being removed and frozen at -70°C 
every hour. Virus extracts were prepared by freezing and thawing the 
samples three times, sonicating for 30 seconds and low speed centrifugation 
to remove cell debris* The supernatants were then titrated by the 
plaque assay technique as previously described. The variations of 
virus titre with time were then plotted to show a virus growth curve.
To test the influence of inhibition on the replication of virus 
the infected monolayers were fed with maintenance medium containing 
doubling dilutions of test compound and incubated at 37°C for a single 
cycle of virus growth. Virus control cultures with only maintenance 
medium were also prepared under the same conditions. After incubation 
virus extracts were prepared as before and titrated by plaque assay.
The resultant dose-response lines were then compared for differences 
in sensitivity.
RESULTS
3.1 TYPE DIFFERENTIATION
Many systems have been used to differentiate strains of herpes 
virus, and the following three have been chosen for this particular work: 
pock size and morphology on the chorioallantoic membrane; plaque size 
in VERO cells; and the nature of the cytopathic effect produced in 
VERO cells. The findings from these three features were then correlated 
with the site of virus isolation.
3.1.1 Pock size determination in eggs
Differences in pock size, in embryonated hens' eggs, have been 
found to be a reliable criterion of herpes virus type, and therefore the 
strains used were typed by this method. The diameters of the pocks 
produced on the chorioallantoic membrane (CAM) by the method previously 
described (2.2.1) were measured and compared by means of a histogram 
(Fig. 3.1). Membranes infected with the individual strains were 
photographed and lantern slides were prepared. This enabled accurate 
measurements of the enlarged pocks to be made when the slides were 
projected on to a screen. No deterioration of the contrast of the 
edge of the pock was observed when displayed in this manner. Dividers 
were used to obtain 3 measurements of each pock diameter, of which the 
mean was taken. A total of at least 20 pocks was measured for each 
virus strain.
The measurements fell clearly into two distinct groups, those which 
had diameters of between 0.1 mm and 0.4 mm, which were produced by 
virus isolates from an oral source, and those which gave diameters of 
between 0.6 mm and 1.2 mm, which were produced by virus isolates of 
genital origin (Fig. 3.1). The appearance of the pocks produced by
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the individual strains is shown in Fig. 3.2. These results correspond 
with those quoted by other workers in the field. Strains producing pocks 
of diameter <0.5 mm were therefore classed as type 1 and strains producing 
pocks of diameter >0.5 mm were classed as type 2.
Another quantitative differentiation briefly examined was based on 
the fact that type 2 strains invaded all three layers of the CAM, the 
ectoderm, mesoderm and endoderm, whereas type 1 strains proliferated only 
in the ectoderm. These latter pocks can therefore be readily detached 
from the CAM, whereas type 2 pocks cannot. This was tested with the 
pocks already produced, and correlation was found beteen the detachability 
of the pocks and the type of the virus according to the pock size.
3.1.2 Plaque size in VERO cells
Variations in plaque size in many cell lines have been recorded 
for herpes virus types 1 and 2, and it was noted that such differences 
occurred in VERO cells (Leinikki, 1971). This was examined with the 
strains with which plaquing had been achieved, namely 2, 3, 5, 6, 11,
21, 22, 24, 27 and 28.
All cultures infected with these strains were incubated for exactly 
the same time (96 hours), before being examined for plaque formation by 
means of staining with methyl violet. The stained cultures were examined 
under a 10X objective of a binocular microscope and the mean of 80 plaque 
measurements for each strain was recorded (Table 3.1). Strains 2, 5, 6 
and 11 produced small focal plaques between 0.4 and 0.5 mm in diameter, 
and strains 21, 22, 24 and 28 produced larger, more open plaques between 
0.8 and 1 mm in diameter. Two strains were found to produce plaques 
intermediate to the two main groups, i.e. strains 3 and 27, with diameters 
of 0.63 and 0.65 mm respectively. The focal nature of strain 3, however,
TABLE 3.1 MEAN PLAQUE DIAMETERS MEASURED ON A SAMPLE OF 80 PLAQUES 
FOR EACH STRAIN
Strain Mean diameter (mm) Standard deviation
2 0.415 0.11
3 0.63 0.16
5 0.49 0.11
6 0.503 0.14
11 0.48 0.16
21 0.92 0.23
22 0.97 0.23
24 0.88 0.26
27 0.65 0.18
28 0.82 0.22
indicated that this was nevertheless a type 1 strain. This same focal 
nature of the plaques was produced by strain 27, which had previously been 
typed by pock morphology as type 2, but this was not considered sufficient 
evidence for reversing the type established by the preceding method. 
Examples of type 1 and type 2 plaques in VERO cells are shown in Fig. 3.3.
3.1.3 Cytopathic effect in VERO cells
Differences in cytopathic effect were studied in Leighton tube 
cultures of VERO cells infected with strains 2, 3, 5, 6, 11, 21, 22, 24,
27 and 28. The infected cultures were stained with haematoxylin and 
eosin after varying periods of incubation and examined, and differences 
in cytopathic effect were observed. Certain strains produced foci in 
which the infected cells heaped up on top of each other; other strains 
produced a more open cytopathic effect with small clusters of rounded cells 
interspersed with multinucleate cells (Fig. 3.4). The former type
produced a more open type of cytopathic effect after longer periods of 
incubation, since the infected cells died and dropped from the growing 
surface. Therefore the early stages of infection were characteristic, 
but when the monolayers were extensively infected differences were 
difficult to detect. The results showed that strains 2, 3, 5, 6 and 11 
produced a proliferative effect and corresponded to the type 1 grouping 
established by pock morphology, but in addition strain 27 produced a 
similar effect. The strains 21, 22, 24 and 28 all produced the more 
open cytopathic effect, again corresponding to the type 2 grouping 
established by pock morphology.
Type 1, strain 5
Fig. 3c3b Type 2, strain 21
Fig. 3.3 Type differences observed in plaque morphology in VERO cells
Fig. 3.4a Uninfected VERO cells - 24 hours incubation
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Fig. 3.4b Uninfected VERO cells - 48 hours incubation
Figs. 3.4 a~h Monolayers of VERO cells infected with herpes virus strain 5 
or strain 21 showing the progression of infection in comparison with controls. 
After incubation all cultures were stained with haeinatoxylin and eosin and 
photographed at a magnification of x320.
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Fig. 3.4c Strain 5, 24 hours after infection
Fig. 3.4d Strain 5, 36 hours after infection
Fig. 3.4e Strain 5, 48 hours after infection 
Fig. 3.4 continued
Fig. 3.4f Strain 21, 24 hours after infection
Fig. 3.4g Strain 21, 36 hours after infection
Fig. 3.4h Strain 21, 48 hours after infection 
Fig. 3.4 continued
5.2 ANTIVIRAL ACTIVITY IN ANIMALS 
3.2.1 Mice
The prolongation of survival times after subcutaneous treatment 
could be used as a response for detecting antiviral activity, provided 
that it is correlated in some way with the extent of multiplication of 
the virus.
(a) Investigation of regression of response on virus dose
In order to simplify the statistical treatment of the results it is 
desirable that the regression of response on virus dose should be linear. 
Attempts were therefore made to determine whether the strains of herpes 
chosen for this work gave linear responses. These strains were first 
adapted to growth in the mouse brain by serial passage, and stocks were 
prepared from infected brain material. Groups of 10 Swiss mice were 
inoculated intracerebrally with 0.025 ml volumes of serial tenfold 
dilutions of virus (either the type 1 strain 11 or the type 2 strain 31). 
The survival times of the animals were then recorded over a 21 day period 
and the reciprocal survival times for each animal were calculated. The 
animals which survived after this time were recorded as having survival 
times of infinity, giving a reciprocal of zero which could be used in 
calculating the mean (Table 3.2). The mean reciprocal survival times 
were then plotted against the log of the virus dose (Fig. 3.5). The
slopes of the lines were calculated from the experimental data by the
method of least squares from the equation :
Xxy - Ixjy/n 
Xx 2 - ( Xx)2/n
where b = slope; x = log virus dose; y = mean reciprocal survival time
and n = total number of animals.
TABLE 3.2 COMPARISON OF SURVIVAL TIMES OF MICE INFECTED INTRACEREBRALLY 
WITH HERPES TYPES 1 AND 2
Herpes type 1 strain 11
Virus
dilution
10-1
10-2
Survival time of each 
animal in days
4 4 4 4 4j 5 6 6 7 7
5 5 6 6 6 6 8 8 8 8
Mean reciprocal 
survival time
0.2071
0.1567
10-3 6 8 8 8 8 10 10 13 S S 0.0943
10-4 12 16 18 21 S S S S S S 0.0250
10-5 All survived
Mean slope b = -0.0599
Herpes type 2 strain 31
Virus
dilution
10
10-2
Survival time of each 
animal in days
-1 3 3 3 3j 3| 5 6| 7
3j 4 4 4 6f 8 11
Mean reciprocal 
survival time
0.2585
0.1950
10-3 5 5 5 6 6j 8^ 11 13 14 S 0.1277
10-4 5 5f 7 8% Si &i 16 S S S 0.0951
10-5 7i .9 11 15 S S S S S S 0.0413
Mean slope b = -0.0531
S = survived
I-*-
0-2
</)
Q.
01
Log of virus dose
Fig. 3.5 Regression of reciprocal survival times on the log of
the virus dose, determined in mice infected w ith herpes 
virus types 1 and 2
• ------- •  Herpes virus type 1, strain 11
A  Herpes virus type 2, s tra in31
The slopes thus obtained were -0.0599 for type 1 and -0.0531 for type 2. 
The closeness of the slopes indicates a similarity in the nature of the 
infection caused by the two strains when inoculated by the intracerebral 
route. The LD50 of the strains of virus used were calculated by the 
Karber method (Karber, 1931), and were 5.3 log unit/ml for type 1 and
6.2 log unit/ml for type 2.
These results clearly show that both type 1 and type 2 gave a 
linear response to the logarithm of the virus dose on intracerebral 
inoculation.
(b) Detection of antiviral activity
The compounds IUdR, ara-C, ara-A, TFT and ara-DAP were screened 
for antiviral activity in mice. Groups of 5 mice were inoculated 
intracerebrally with 100 LD50 of either type 1 strain 11, or type 2 
strain 31. Subcutaneous treatment was begun 2 - 3  hours later with 
the compounds at a routine concentration of 1 mg/dose. Treatment 
was given twice daily for 4\ days and survival times were recorded over 
a total of 14 days. An increase in survival time was only seen with 
the two purine compounds ara-A and ara-DAP (Table 3.3). Very slight 
increases in survival times were recorded for the pyrimidine nucleosides 
IUdR and TFT, but not for ara-C. The difference in survival time 
recorded for ara-A and ara-DAP is an indication of antiviral activity, 
and a difference of this order warrants further investigation for the 
purpose of determining the relative potencies of the compounds.
(c) Assay of antiviral activity
The linear responses given by the two strains of herpes virus were 
used to determine the relative potencies of ara-A and ara-DAP, the two 
compounds found active in mice. Groups of 5 Swiss mice were inoculated 
intracerebrally with either 100 or 1 LD50 of virus and treated for 4\ days
TABLE 3.3 DETECTION OF ANTIVIRAL ACTIVITY IN MICE: SURVIVAL TIMES
AND MEAN RECIPROCALS RECORDED FOR IUdR, ARA-C, ARA-A, TFT 
AND ARA-DAP AGAINST HERPES TYPE 1 STRAIN 11 AND TYPE 2 STRAIN 31
Type 1 strain 11
Compound
IUdR
ara-C
ara-A
TFT
ara-DAP 
Virus control
Survival time (days)
4
4
5 
4
6
3f
4} 5} 5^
42 4
6 7
Mean reciprocal 
survival time
0.1953
0.2186
0.1527
0.1956
0.1460
0.2125
Type 2 strain 31
Compound
IUdR
ara-C
ara-A
TFT
ara-DAP 
Virus control
Survival time (days)
4 4
Zi Zi
7
4
7
z i
4
1
4
7
4
5
5
5
8
5 
8 
4
6
Mean reciprocal 
survival time
0.2186
0.2443
0.1293
0.2078
0.1329
0.2227
twice daily with 0,1 ml volumes containing 1 mg of drug suspension 
(neither compound was soluble at this concentration). The survival times 
were recorded for 14 days (Tables 3.4 and 3.5), and dose-response lines 
were constructed from the mean reciprocal survival times (Fig. 3.6).
The mean slope was calculated from the pooled responses in the treated 
and control groups, so as to give parallel dose-response lines. The 
relative potencies (Table 3.6) were then calculated from the horizontal 
distance between the lines from the equation :
Log R log xg - log xt - (yx - y^ b " 1
Xs = ' mean control virus dose
= mean treated virus dose
V
= mean response of control group
h = mean response of treated group
b = . slope of regression line
TABLE 3.4 SURVIVAL TIMES OF HERPES INFECTED MICE TREATED
SUBCUTANEOUSLY WITH 9-(3-D-ARABINOFURANOSYLADENINE
Type 1 strain 11
CONTROL TREATED
Virus Survival time Mean reciprocal Survival time Mean reciprocal
dilution (days) survival time (days) survival time
10~2 4 4 5j 6 0.2268 4 5^ 6^ 8^ 9j 0.1617
10“4 6 8 lOf S S 0.0774 9 S S S S 0.0222
Mean slope b = -0.072
Type 2 strain 31
CONTROL TREATED
Virus Survival time Mean reciprocal Survival time Mean reciprocal
dilution (days) survival time (days) survival time
10~2 3 4 4 4 5 0.2566 4 5 5 7 8 0.1836
10“4 6 7 8 8 12 0.1286 8 8 10 12 12 0.1033
Mean slope b = -0.052
S = survived
TABLE 3.5 SURVIVAL TIMES OF HERPES INFECTED MICE TREATED SUBCUTANEOUSLY
WITH 2, 6-DIAMINO-9-(3-D-ARABINOFURANOSYLPURINE
Type 1 strain 11
CONTROL TREATED
Virus Survival time Mean reciprocal Survival time Mean reciprocal
dilution (days) survival time (days) survival time
10~2 4 4 6 6 0.2111 6 7 7 9 10 0.1325
10~4 7 9j llj S S 0.0670 8 14 S S S 0.0393
Mean slope b = -0.059
Type 2 strain 31
CONTROL TREATED
Virus Survival time Mean reciprocal Survival time Mean reciprocal
dilution (days) survival time (days) survival time
10“2 3} 4 4 4 4 0.2571 6 7 7 8 8 0.1405
10~4 6 8 8j Q% 9 0.1236 10 S S S S 0.0200
Mean slope b = -0.062
S = survived
9 -B  -D -arab ino furanosy  ladenine
type 1, strain 11
Log of virus dose
type 2, strain 31
i
Log of virus dose
2 , 6-diamino-9-B-D-arabinofuranosylpurine
type 1, strain 11
i
Log of virus dose
type 2, strain 31
i
i
Log of virus dose
Fig. 3 .6  Comparison of the sensitivies of herpes types 1 and 2 to 
treatment, in mice, with 9-B-D-arabinofuranosyladenine and 
2 , 6-diam ino-9-B -D - arabinofuranosylpurine
a □ mean values for control animals 
▲ ■ mean values for treated animals
TABLE 3.6 COMPARISON OF THE ANTIVIRAL ACTIVITIES OF ARA-A AND ARA-DAP 
AGAINST HERPES VIRUS TYPES 1 (STRAIN ll) AND 2 (STRAIN 31)
Ara-A Ara-DAP
Mean slope (b) p|“ 7 R) Mean slope <b)
Herpes type 1
strain 11 -0.072 0.83 -0.059 0.89
Herpes type 2
strain 31 -0.052 0.94 -0.062 1.70
3.2.2 Rabbit eye infections
(a) Titrations of virus stocks
Experimentally induced herpetic keratitis in rabbits was used to
compare the sensitivities of infections caused by type 1 (strain ll) and
type 2 (strain 21) to treatment with IUdR, ara-C, ara-A, TFT and ara-DAP.
Tissue culture stocks of virus were used for this technique, and were
firstly titrated in the rabbit eye by the method of Jones et al. (1968).
The infections were allowed to proceed for 72 hours and the appearance
of the lesions was recorded. Exact titres could not be obtained by this
method, as after 72 hours the infections had spread to produce punctate
and dendritic ulceration over the whole surface of the cornea. Therefore
the working concentrations of virus were estimated by inoculating
individual eyes with a single concentration of virus in the form of a
-2
cross of 8 insertions. As a result 10 dilutions of both type 1 and
type 2 strains were found to be the most favourable inoculum concentration
-2for use, since dilutions above 10 gave inconsistent levels of infection, 
and lower dilutions produced infections which were too severe. After 
72 hours infection with the chosen concentration resulted in general 
punctate and dendritic ulceration of the cornea with slight injection of 
the limbus, conjunctivitis and a slight amount of discharge.
(b) Evaluation of antiviral activity
Both the efficacy of the compounds and the sensitivity of the 
strains used to the test compounds were investigated by this technique.
The condition of the eyes of infected rabbits was recorded after 72 hours 
by the method described by Corwin (1963), and treatment was begun and 
continued for 4 days; 5 doses were given per day in the form of eye-drops 
at intervals of 2 hours. The condition of the eyes was scored on the 
morning of each day, and on the seventh day of infection the animals
were killed. The conditions of both treated and control eyes at this 
time are summarized in Table 3.7, and the progression of the infections 
is shown in Figs. 3.7 - 11.
All compounds showed good activity against the type 1 strain.
Deeper involvement only occurred in rabbit 3 and this was prevented in 
the treated eye. Rabbits infected with the type 2 strain frequently 
produced deeper infections which were only prevented on two occasions, 
in rabbit 12 with IUdR and in rabbit 18 with TFT. The activity of the 
compounds appeared less than that observed against type 1 infections.
After a successful treatment the stained area of the cornea was 
reduced to almost zero and the previously damaged corneal epithelial 
cells were healing and being replaced. The surface appeared less 
indented than that of the infected corneas (Figs. 3.12, 3.13). Control 
or unsuccessfully treated eyes often showed corneal opacities. By this 
time the conjunctiva had become very swollen with excessive discharge, 
which may have been due to secondary bacterial infection, as on one 
occasion micrococci would be isolated from the eye. Such severe 
infections may penetrate the cornea, especially in the case of type 2 
strains, the infection passing through the stroma and giving rise to 
iritis. If allowed to proceed the infection passes to the optic nerve 
and subsequently to the brain, causing encephalitis and death. Type 1 
infections, however, are seldom so severe as to pass through the stroma, 
and remain on the corneal surface, thus being self-limiting. Severe 
infections show typical geographic ulceration, so that almost all the 
corneal surface takes up the stain. Animals reaching such a condition 
were killed, whether or not the experiment had been completed.
All compounds were administered as a solution with 0.01% 
benzalkonium chloride as a bacteriostatic agent, but they were not all 
completely soluble at 0.5%, which was the standard concentration tested.
TABLE 3.7 TREATMENT OF HERPETIC KERATITIS IN RABBITS
Herpes type 1 (strain 11)
Compound RabbitNo. A
B C Score x 2 D E
Score 
x 10
Total
score Iritis
Activit
IUdR 1 C 2 2 2 12 2 3 50 62 . X X
T 1 1 1 6 0 1 10 16 -
T T
2 C 1 2 2 10 2 3 50 60 ++
T 1 1 1 6 0 1 10 16 -
Ara-C 3 C 2 3 3 16 2 3 50 66 + X X
T 0 1 1 4 0 1 10 14 -
T T
4 C 2 2 1 10 2 3 50 60 MB ++
T 0 0 1 2 1 1 20 22 -
Ara-A 5 C 1 2 1 8 2 2 40 48 MB
T 0 0 1 2 0 1 10 12 -
T T
6 C 2 2 2 12 2 3 50 62 MB ++
T 1 1 1 6 0 1 10 16 -
TFT 7 C 1 2 2 10 2 3 50 60 _
X X
T 0 1 0 2 0 0 0 2 -
T T
8 C 1 . 2 3 12 2 3 50 62 MB '
T 1 1 0 4 0 1 10 14 •
T T
Ara-DAP 9 C 1 1 2 8 2 3 50 58 _ •XX-
T 1 1 1 6 0 1 10 16
T T
10 C 1 2 1 8 1 2 30 38 «B X X
T 0 1 0 2 0 0 0 2
T T
C and T represent control and test eyes for individual rabbits
A = Injection of the limbic blood vessels
B = Oedema of conjunctiva and lids 
C = Discharge
D = Opacity of cornea
E = Area of infection
++ = Good activity
+ = Activity
—  = No activity
Treatment commenced 3 days after infection and the condition of eyes 
was recorded 4 days later.
TABLE 3,7 (continued) 
Herpes type 2 (strain 21)
Compound Rabbit
No.
A B C Score x 2 D
E Score 
x 10
Total
score Iritis
Activit
IUdR 11 C 2 2 1 10 1 2 30 40 + -J.
T 2 2 10 0 1 10 20 +
12 C 2 2 10 1 2 30 40 +
T 1 2 8 0 1 10 18 -
Ara-C 13 C 3 2 1 12 1 2 30 42 + 4-
T 2 2 1 10 0 1 10 20 +
T
14 C 2 3 2 14 2 2 40 54 + +
T 2 2 1 10 0 1 10 20 +
Ara-A 15 C 2 2 2 12 3 4 70 82 x.
T 2 2 2 12 2 2 40 52 -
T
16 C 1 2 2 10 3 3 60 70 +
T 2 2 3 14 3 2 50 64 +
TFT 17 C 2 1 2 10 2 2 40 50 + x
T 2 2 1 10 1 1 20 30 + ■
T
18 C 2 2 3 14 3 3 60 74 +
T 1 1 2 8 0 1 10 18 -
T T
Ara-DAP 19 C 1 2 1 8 1 2 30 38
T 1 2 1 8 0 0 0 8 -
+
20 C 2 3 2 14 2 4 60 74 +
T 3 3 3 18 2 3 50 68 +
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IUdR was found to be soluble on warming and remained in solution on 
storage at 4°C. Both ara-C and TFT were completely soluble and presented 
no problems. Ara-A and ara-DAP had low solubilities, and although they 
dissolved on warming, they quickly precipitated on storage to form a 
suspension. The solubilities of these compounds were examined 
spectrophotoraetrically, and the aqueous phases of 0.5% suspensions 
contained 13% of the total amount of ara-A and 14% of the total amount 
of ara-DAP. It is debatable whether drug suspensions are more or less 
satisfactory for the treatment of eye infections in rabbits: they may
prolong the availability of the drug before being washed away in the 
tears, or they may be irritant to the eye surface by virtue of the 
solid particles which they contain.
All the compounds used in treatment showed considerable activity 
against the type 1 strain since the surface involvement was almost 
eradicated after 4 days treatment, and secondary signs were much reduced 
in the same time. Scoring by the Corwin method tends to be biassed 
towards type 1 infections, as in many type 2 infections the eye becomes 
more deeply involved, which is not taken into account in this method. 
Surface infections with type 2 strains were treated successfully, but 
in many cases deeper involvement was not prevented. By the Corwin 
method ara-A was shown to be more effective against type 1 than against 
type 2 infections. Lesser differences were noted with the remaining 
compounds, although type 1 strains appeared the more sensitive.
3.3 ANTIVIRAL ACTIVITY IN CELL CULTURE
3.3.1 Plaque inhibition test
Antiviral activity is demonstrated by the zone of protection 
resulting from radial diffusion of the test compound from its source 
through the solid overlay, which gives rise to a zone of inhibition of 
plaque formation. It was necessary to know whether the zone of 
inhibition was related in a linear fashion to the amount of compound 
on the disc. An experiment was performed with a type 1 strain (.11) 
and a type 2 strain (21) to demonstrate that the size of the zone was 
a measure of antiviral activity. Confluent monolayers of VERO cells 
were prepared and infected with the appropriate virus. After the 
infected cells were overlaid filter paper discs containing 12.5, 25,
50 and 100 pg of ara-C were placed on the centre of the overlay and 
tested in duplicate. The plates were incubated for 96 hours and the 
diameters of the zones were measured 4 times, the mean values of which 
were recorded (Table 3.8). Graphical comparisons of the relationship 
were made by plotting the square of the radius against the log of the 
compound concentration (Fig. 3.14). The relationship was found to be 
linear for both strains, which indicates that the effect shown is a 
measure of antiviral activity.
It was also necessary to determine whether the virus concentration
affected the size of the zone of protection. Stocks of strain 21 were
—3 —5
diluted in \ dilutions frora 10 to 10 . Triplicate VERO cell
cultures were infected with each dilution and the overlaid cultures 
were treated with discs containing 50 pg IUdR. The resultant zones 
were measured and compared (Table 3.9). No significant differences
were observed for the zones in the 10 ,10 * and 10 plates. A
-4.5 .slight increase was recorded at 10 , where plaques were becoming
-5
sparse and the edge of the zone was difficult to determine. At 10
TABLE 3.8 RELATIONSHIP BETWEEN DIAMETER OF THE ZONE OF PROTECTION 
AND AMOUNT OF 1-p-D-ARABINOFURANOSYLCYTOSINE
Herpes type 1 strain 11 Herpes type 2 strain 21
Amount on Zone diam. Mean diam 
disc (ug) (mm) (mm)
12.5 41 44 42.5
25 49 53 51
50 63 65 64
100 72 76 74
2
R = square
r% Zone diam. Mean diam. O
R (mm) (mm) R
452.5 38 40 39 380.25
650 50 47 48.5 588
1022 59 57 58 841
1369 68 64 66 1089
the radius
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Fig. 3.14 Plaque inhibition test results, expressed as radii squared, 
recorded for doubling dilutions of a r a - C  against  
strains 11 and 21, demonstrating a l in e a r  reponse 
between the size of the zone and the concentration  
of the compound.
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TABLE 3.9 EFFECT OF VIRUS DOSE UPON THE RESULTANT ZONE OF 
PROTECTION WITH IDOXURIDINE AT 50 jig/DISC
Virus dilution Zone diameter Mean diameter
(strain 21) (mm) (mm)_____
10-3 22 23 24 23
,10-3*5 24 23 20 22.3
10“4 23 22 22 22.3
10“4*5 26 27 26 26.3
the plaques were too few for any measurement of zone diameter to be 
made.
Antiviral activity was detected for all five compounds under test 
and the resultant zones of inhibition were used to compare their 
activities. The compounds were tested at 50 p.g/disc against the 
type 1 strains 2, 3, 5, 6 and 11 and the type 2 strains 21, 22, 24, 27 
and 28, and the zone diameters recorded were the mean of 4 measurements 
of each zone (Table 3.10). The results were displayed by means of a 
scatter diagram (Fig. 3.15). Activity was observed with all compounds, 
and against all strains except in the case of ara-DAP, which failed to 
give results against the type 1 strains 3 and 6 and the type 2 strains 
21, 24, 27 and 28. Small zones were occasionally observed with these 
strains but were less than 5 mm and were difficult to measure accurately. 
These strains were frequently re-tested with similar results. Ara-C was 
clearly the most active compound, giving zones of protection from 50 mm 
to 85 mm. Differences in strain and type sensitivities, which can be 
seen from the scatter diagram, will be discussed in a later section.
As a technique plaque inhibition was found to be a most successful 
and rapid method for detecting antiviral activity against herpes virus 
types 1 and 2. It did not appear to be sufficiently sensitive for the 
fine evaluation of antiviral activity when closely related analogues are 
compared. However, it gives early indications of what may be found when 
more quantitative techniques are used. It must be stressed at this point 
that all compounds tested were at a concentration of 50 jig/disc, and 
comparisons of activity should be made on a molar basis. At the same 
time differences in diffusion rates and solubilities of the compounds may 
affect the diameters of the zones of inhibition and give a false impression 
of their relative activities.
TABLE 3.10 ZONE DIAMETERS RECORDED FOR IUdR, ARA-C, ARA-A, 
TFT AND ARA-DAP. AT 50 pg/DISC
Compound
VIRUS STRAINS
2 3
Type 1 
5 6 11 21 22
Type 2 
24 27 28
IUdR 38 33 37 36 36 20 20 23 37 24
36 32 36 38 37 23 17.5 24 37 26
mean 37 32.5 36.5 37 36.5 21.5 19.9 23.5 37 25
ara-C 85 80 85 77 70 59 50
%
60 62 62
85 74 85 83 75 61 52 61 65 63
76 52
54
mean 85 77 85 80 73.5 60 52 60.5 63.5 62.5
ara-A 33 28 36 33 45 21 27 27 29 25
32 34 34 36 37 23 33 32 32 23
38 35
45 37
mean 32.3 31 35 34.5 41.25 22 33 29.5 30.5 24
TFT 55 34 50 39 30 36 28 32 35 38
48 30 53 44 32 34 25 27 29 36
34 47 30 27 28
36
mean 51.5 33.6 51.5 43.5 30.6 35 26.6 28.3 30.6 37
ara-DAP 17 + 23 + 20 + 13 + + +
18 25 22 14
17 19
mean 17.5 + 22 + 19.6 + 15.3 + + +
Activity observed but zone less than 5 mm and 
therefore difficult to measure accurately.
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3.3.2 Tube culture test
Initial studies in tubes were performed by comparing the times
taken for cultures infected with increasing amounts of virus to reach
50% cytopathic effect (CPE) in the presence and absence of test compound
at standard concentrations. These preliminary experiments were
performed in HEp.2 cells with the type 1 strain 11 and the type 2 strain
—2 -3.522. Half-log^ dilutions of the virus were prepared from 10 to 10 
from the original tissue culture stocks and groups of 6 tubes were infected 
with each dilution. After an adsorption period of one hour the inocula 
were removed and the tubes were fed with either maintenance medium or 
maintenance medium supplemented with IUdR to a final concentration of 
100 jiM. The cultures were incubated in a rolling machine and examined 
twice daily for 5 days and the survival times of each culture were recorded 
as the times taken to reach 50% CPE. The means of the reciprocals of 
these survival times were plotted against the virus dilution to give 
control and test lines, which were almost parallel. Parallel plots were 
prepared by pooling both test and control results for one virus strain 
and calculating a mean slope by the method of least squares (Fig. 3.16).
The slopes calculated were as follows: type 1 strain 11, -0.098;
type 2 strain 22, -0.148. It can be seen from the displacement of the 
line that IUdR has antiviral activity. The extent of this activity may 
be quantified by calculation of the relative potency of the compound, 
i.e. the horizontal distance between the two lines, from the equation 
given in section 3.2.1(c).
The type 1 strain 11 and the type 2 strain 22 gave relative potencies 
of 0.80 and 0.66 respectively. It is evident that IUdR has a higher 
relative potency against strain 11 than strain 22. However, at this 
point one must consider the slopes of the lines concerned. The type 2 
strain gave a higher slope; the lower slope of the type 1 strain therefore
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resulted in a greater horizontal distance between the treated and control 
.lines and a greater relative potency. In order to make more valid 
comparisons between strains the slopes must be identical, because although 
the effects may appear similar at first glance, small variations in slope 
may bring about large variations in relative potency.
It was also felt that the estimation of results from the 50$ endpoints 
was too subjective and that errors could easily range as far as 15$ 
either side of the 50$ level. The time that the first discrete foci 
of CPE could be detected was therefore accepted as a more reliable measure 
of CPE.
At this time the cell culture work was transferred to VERO cells 
because of the establishment of the plaque assay technique in these cells, 
and they were therefore used for all subsequent tube culture studies.
The extent of the delay in viral replication under the influence of 
a chemotherapeutic agent was expressed as the delay in appearance of CPE, 
and was calculated as the time difference between the first detection of 
CPE in control and treated cultures. The sensitivities of the type 1 
strains 2, 3, 5, 6 and 11 and the type 2 strains 21, 22, 24, 27 and 28 
were examined against IUdR, ara-C, ara-A, TFT and ara-DAP by this 
technique. The titres of the original tissue culture stocks were 
determined by the Karber method (Karber, 1931) from preliminary titrations 
in VERO cell tube cultures, and doses of 1, 10 and 100 TCID50/ml were 
used for infection (Table 3.11). The results were based on 50$ CPE 
after 48 hours incubation at 35°C.
VERO tube cultures were infected with virus and then treated with 
one of the test compounds at the following concentrations: ara-C, 2.5 pM;
IUdR, ara-A and TFT, 10 pM; ara-DAP, 20 pM; 3 treated and 3 control 
cultures were set up for each virus dilution. Tubes were examined
TABLE 3.11 TITRES OF TISSUE CULTURE VIRUS STOCKS DETERMINED 
BY INFECTIVITY TITRATIONS IN TUBE CULTURES
Type 1 strains Titre (TCID50/ml) Type 2 strains Titre (TCID50/raI)
104 21 105
104,5 22 104,75
104*5 24 104
4 4
10 27 10
11 104,75 28 103*75
twice daily and the delay in appearance of CPE was determined. The 
values obtained were plotted against virus dilution (Fig. 3.17).
It is evident from these graphs and the concentrations of compound 
used that ara-C was the most active compound against the strains of 
herpes virus used. Long delays in the appearance of CPE were observed 
at the 1 and 10 TCID50 levels, but at 100 TCID50 the CPE developed 
rapidly and without frequent examination the estimates of first detection 
of CPE are inaccurate. This holds for all the compounds tested, the 
delay being somewhere in the range of 0 - 10 hours at 100 TCID50. The 
compounds tested at 10 pM (IUdR, ara-A and TFT) all produced similar 
responses, as did ara-DAP at 20 pM. These delays, however, were 
markedly lower than those recorded for ara-C.
Closer examination of these graphs gives no real evidence of 
differential susceptibility between types 1 and 2. All the response 
lines overlap to a great extent, and differences in sensitivity can only 
be seen by selecting particular strains. Strains 3, 6, 11, 22 and 27 
were generally of higher sensitivity than strains 2, 5, 21, 24 and 28, 
although there was some degree of overlap and the differences between 
the individual strains was always slight, except possibly with ara-C 
tested against 1 TCID50 of virus. These features will all be examined 
further in the discussion.
3.3.3 Microtitre plate test
Attempts were made to substantiate the infectivity results obtained
in tube cultures by the use of the more rapid microtitre technique.
Initial studies were performed with 4 strains of herpes virus, namely
2, 5, 21 and 28, which were titrated in VERO cells cultured in microtitre
4 1plates. The following titres were obtained: strain 2, 10 TCID50/ral;
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strain 5, 10 * TCID50/ml; strain 21, 10 * TCID50/ml; and strain 28, 
104*35 TCID50/ml.
Initial studies were then performed to determine the working 
concentrations of compounds to be used, which were found to be as follows: 
IUdR, 10 pM; ara-C, 2.5 pM; TFT, 5 pM; ara-A and ara-DAP, 20 pM.
These concentrations were then tested against 1 and 10 TCID50 of virus. 
Microtitre plate wells were seeded with VERO cells, the appropriate virus 
and test compound, before being sealed and incubated at 37°C (2.5.5).
Up to 5 replicates were prepared for each individual concentration, and 
the extent of CPE was recorded twice daily.
Delay in the appearance of CPE was again the criterion used to 
demonstrate an antiviral effect, and it was hoped that consistent 
differences between cultures infected with either 1 or 10 TCID50 virus 
would make type and strain comparisons quite feasible. The mean values 
for delay in appearance of CPE are shown in Table 3.12. These results 
were found to be very variable and plots of the delay in appearance of 
CPE against virus inoculum were examined but were found to be of no use 
in comparing sensitivities. On many occasions the delay was found to 
be the same for cultures infected with both 1 and 10 TCID50, and on 
two occasions (5 pM TFT against strains 21 and 28) the delay was greater 
at 10 TCID50 than it was at 1 TCID50.
This technique, although rapid and easily carried out, was found to 
be unreliable, and meaningful results were not always readily obtained. 
Problems with surface tension were felt to be the root of the troubles, 
since the cells grouped around the periphery of the wells, which frequently 
led to gaps appearing in the monolayers. This grouping of cells obviously 
made the detection of CPE difficult, and therefore only the 4 strains 
mentioned above were tested by this method.
TABLE 3* 12 DELAY IN APPEARANCE OF CYTOPATHIC EFFECT (HOURS) FOR IUdR, 
ARA-C, ARA-A, TFT AND ARA-DAP AGAINST THE TYPE 1 STRAINS 2 
AND 5 AND THE TYPE 2 STRAINS 21 AND 28
Virus
IUdR Ara*-C Ara-A TFT Ara*-DAP
strain 1* 10* 1 10 1 10 1 10 1 10
2 18 18
.
18
.
6 24 18 12 6 24 12
5 18 18 12 6 24 18 18 12 12 12
21 24 12 18 12 18 6 6 12 6 6
28 12 12 12 6 12 6 6 12 12 12
Virus dose TCID50/ml.
3.3.4 Gradient plate plaque reduction test
It was hoped that the gradient plate plaque reduction technique 
would afford a preliminary quantitation of the antiviral activities of 
IUdR, ara-C, ara-A, TFT and ara-DAP by a plaque dependent method, thus 
giving an indication of the ranges of concentrations which should be 
used in tests by other plaque techniques.
Preliminary studies were performed in human embryo lung cells, and 
although no plaques were produced by the two strains used (11 and 22) 
in these cells, some indications were obtained by observing the cut-off 
of CPE. When a plaque assay technique was developed in VERO cells 
attempts were made to obtain more accurate results by this technique.
Confluent VERO cell cultures were infected with sufficient herpes 
virus type 1 strain 11 or type 2 strain 22 to produce 400 - 500 plaques 
per flask. Overlays were then added as described (2.5.6). The maximum 
concentrations of compounds used were as follows: IUdR, 150 pM;
ara-C, 50 pM; ara-A, 200 pM; TFT, 100 pM. Ara-DAP failed to give 
any meaningful results because toxicity was observed above approximately 
90 pM. Minimal amounts of toxicity were also observed with TFT at the 
higher concentrations tested.
All gradients of maximum concentrations were tested in triplicate 
and both the resultant mean d^ values (the point of complete plaque 
suppression) and the mean MIC values are given in Table 3.13. A typical 
example of a gradient plate is shown in Fig. 3.18. The MIC values 
obtained quite clearly show that ara-C is the most active compound, with an 
MIC of about 5 pM, followed by TFT with an MIC of about 50 pM. Ara-A and
IUdR were the least active, with MIC values of 76.2 and 69.5 pM respectively
against type 1 virus. Type 2 was found to be less sensitive to IUdR,
with an MIC of 82.5 pM compared to 67.5 pM for ara-A. It would appear
TABLE 3.13 MEAN d£ AND MINIMUM INHIBITORY CONCENTRATIONS (pM) OBTAINED 
FOR IUdR, ARA-C, ARA-A AND TFT AGAINST STRAINS 11 AND 22 BY 
THE GRADIENT PLATE PLAQUE REDUCTION TEST
Compound Cone.(pM)
Herpes virus type 1 strain 11 Herpes virus type 2 strain 22
d.l MIC d.l MIC
IUdR 150 35.67 69.5 42.3 82.5
Ara-C 5 41 5.3 39 5.1
Ara-A 200 58.67 76.2 52 67.5
TFT 100 40 51.9 36.67 47.6
Fig. 3.18a Control
Fig. 3.18b Treated
Fig. 3.18 Gradient plate plaque reduction; effect of 100 pM IUdR 
against type 2, strain 22.
therefore that only IUdR showed any difference in type sensitivity, with 
a difference of 13 pM between the MIC values obtained for type 1 and type 2. 
However, this difference was not significant (p = 0.2 - O.l).
No further strains were tested by this technique since numerous 
problems were encountered, and the technique appeared to be unreliable. 
Firstly, with the low concentrations of agarose used when plaquing in 
VERO cells some of the control and test agarose layers tended to mix, and 
the lower layer of agarose occasionally lifted. Secondly, the line of 
complete suppression of plaques was not always straight because of a 
meniscus effect with the edge of the flask. It was hoped therefore 
that more reliable results would be obtained by the other plaque 
techniques.
3.3.5 Plaque reduction test
In order to quantitate the activities of the 5 compounds, dose- 
response lines were obtained by the plaque reduction technique (2.5.8).
The cultures were incubated for 96 hours as for plaque inhibition (2.5.7). 
This period of incubation gave rise to plaques of a reasonable size for 
counting. Longer incubation periods had no deleterious effect upon 
type 1 plaques; the dead cells disappeared from the centre of the foci, 
but the plaques did not increase in size significantly. With type 2 
plaques, however, there was an increase in size and the plaques tended 
to coalesce and become difficult to count, thus leading to inaccuracies 
in the determination of activity, which gave false high values. It was
found that 200 - 400 plaques per culture after incubation was the most
suitable number, requiring an inoculum of 100 - 200 pfu/ml. This volume, 
although large, gave an even spread of plaques. Smaller volumes gave
rise to plaques only on the periphery of the cultures due to the effect of
the meniscus.
Initial studies were performed with strain 11 to determine the 
activity range of the 5 compounds, before a comprehensive study was made 
with all strains. The follo\*ing ranges were found to be suitable :
0.5 1.0 2.0 4.0 pM
0.25 0.5 1.0 2.0 pM
5 10 20 40 80 pM
These concentrations were then tested against 10 strains and the resultant 
plaque counts were expressed as a percentage of the virus controls 
and plotted against the log of the compound concentration. The 
appearance of the cultures from a typical plaque reduction assay is 
shown in Fig. 3.19, where the number of plaques is visibly reduced as 
the concentration increases.
The dose-response lines were plotted and consistent trends in the 
relative potencies of the compounds were observed, although there were 
some variations between strains (Fig. 3.20), a typical set of results 
being shown in Table 3.14. In general ara-C was found to be the 
most active compound, followed by IUdR, although in 2 cases IUdR gave 
similar activities (strains 21 and 28) and in 2 other cases (strains 2 
and 5) the activities were higher. TFT gave similar results to IUdR, 
especially for the type 1 strains. Against type 2 strains TFT was 
found to be generally more active than IUdR. TFT was inactive against 
strains 21 and 28, even at concentrations as high as 80 pM. Above this 
level some toxicity was observed, so that higher concentrations could not 
be tested. The dose-response lines were therefore horizontal. These 
two strains were therefore presumed to be resistant to TFT.
Both ara-A and ara-DAP showed considerably less activity than IUdR, 
ara-C and TFT, ara-A showing the greater activity of the two. Strains 21
IUdR and TFT 
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Fig. 3.20 Dose-response lines obtained by plaque reduction assays 
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and 28, which were resistant to TFT, were also resistant to ara-DAP, 
and concentrations higher than 80 l^M could not be tested for toxicity 
reasons*
Straight lines were calculated by the method of least squares 
from the individual counts for each of the dose-response lines. The 
correlation coefficients and the slopes of each line were also calculated, 
and a typical set of results for strain 11 is shown in Table 3.15. 
Calculations of the slopes were made using only those results obtained 
from the central, straight portion of the dose-response line. Results 
that approached either 100% or 0% of the virus control were omitted 
from the calculations because of the asymptotic nature of dose-response 
lines. The resultant lines from these calculations are shown in 
Fig. 3.21. The slopes of the lines are shown in Table 3.16.
It was noticeable from the slopes that the majority fell within the 
range -80.00 to -120.00, as shown in Fig. 3.22 in the form of a histogram. 
This histogram includes the slopes for both type 1 and type 2 strains. 
Histograms of the slopes from type 1 and type 2 strains were examined 
individually, but both gave a similar distribution of slopes and therefore 
provided no relevant information for further discussion. Below -120.00 
there was a sharp cut off, but above -60.00 the cut off was far from 
complete. These occurrences were therefore investigated further.
The low slopes were obtained with the compounds TFT and ara-DAP , 
against the type 1 strains 2 and 5. The remaining low slopes were 
recorded for ara-DAP against the type 2 strains 22, 24 and 27; this may 
be explained by the fact that concentrations of ara-DAP above 80 |iM 
could not be tested, as explained earlier, and the results for these 
three strains all gave high percentages of the virus control. This 
would indicate that the counts did not fall on the straight portion of 
the dose-response line. This may be an explanation for the similar
TABLE 3.15 STATISTICAL EVALUATION OF DOSE-RESPONSE FIGURES FROM 
PLAQUE REDUCTION ASSAYS OF IUdR, ARA-C, ARA-A, TFT 
AND ARA-DAP AGAINST HERPES VIRUS TYPE 1 STRAIN 11
All data Limited data
Compound Correlation
coefficient
(r)
Slope y Intercept
Correlation
coefficient
(r)
Slope y Intercep
IUdR -0.96 -78.40 48.97 -0.96 -99.70 45.53
Ara-C -0.93 -73.05 -3.26 -0.97 -116.38 -25.00
Ara-A -1.00 -101.16 168.66 - - -
TFT -0.92 -79.62 39.98 -0.96 -111.53 36.78
Ara-DAP -0.99 -83.90 160.21 -0.98 -79.41 153.92
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Fig. 3.21 The best fit straight lines obtained by the method of least 
squares for lUd R, ara-C , a ra - A, TFT and ara-D A P  against 
each of the 10 strains of herpes virus.
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SLOPES OF DOSE-RESPONSE LINES OF 10 STRAINS OF HERPES 
VIRUS AGAINST IUdR, ARA-C, ARA-A, TFT AND ARA-DAP
IUdR
-76.00
-101.57
-66.09
-92.61
-99.70
-83.06
-70.46
-47.76
-116.81
-89.95
Ara-C
-99.53
-109.81
-87.76
-110.94
-116.38
-56.83
-143.04
-102.61
-102.90
-52.89
Slope
Ara-A
-76.23
-88.52
-116.18
-113.53
-101.16
-111.73
-101.03
-97.37
-136.05
-88.35
TFT
-40.68
-98.24
-37.08
-104.48
-111.53
-94.64
-85.09
-99.55
Ara-DAP
-43.11
-98.06
-49.22
-13.81
-83.90
-29.40
-29.74
-10
Fig. 3 .22
-50 -100
Slope
Distribution of slopes of dose-response lines
-150
low slopes obtained for the type 1 strains 2 and 5, although a greater 
proportion of the dose-response line was covered by the results obtained, 
but again with the inability to test above 80 |iM these features cannot be 
fully explained. If the above reasoning is accepted, however, then it 
must be taken that these strains have a lower sensitivity to these compounds 
than indicated by their slopes.
When the dose-response lines for each of the ten strains were 
examined for each compound it could be seen that ara-C was the most active 
of the compounds tested. There was, however, some overlap with IUdR.
It was also evident that there was a great variation in sensitivity 
between strains and no one strain could be singled out as the most sensitive. 
The type 1 strain 11 showed the most consistently high sensitivity, being 
most sensitive to TFT, ara-DAP and ara-C. One feature that was striking 
was a tendency for type 2 strains to be less sensitive than type 1 strains, 
especially with IUdR, ara-A and ara-DAP, but again there was some overlap.
The subject of strain sensitivity and differences in type sensitivity will, 
however, be more fully examined in the discussion.
3.3.6 Yield reduction test
The plaque reduction technique measures the activity of a compound 
under multiple cycle conditions, i.e. the incubation period is well in 
excess of the generation time of the virus. It was therefore felt that 
study under single cycle conditions might provide additional information.
The technique of yield reduction was chosen, and the test samples were 
titrated by the plaque assay technique.
Strains 11 and 22 were grown over a 24 hour period and samples were 
taken at intervals and titrated; growth curves were constructed from the 
results (Fig. 3.23). The two curves showed the typical form of an early
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Fig. 3.23 Growth cycles of strains 11 and 22 of herpes virus 
grown in VERO cells.
Key: • -----• , strain 11; 'O O ,strain 22.
eclipse phase, steep logarithmic phase and a stationary phase. The 
stationary phase, at which time the yield of virus has attained a 
maximum, was reached after 15 - 18 hours. Therefore 18 hours was 
chosen as the incubation period for all yield experiments.
For both the growth cycles and yield studies cultures were infected 
with multiplicities of virus greater than 1, in the range of 2 - 3, 
ensuring that nearly every cell was infected and that re-infection after 
one growth cycle was unlikely.
Only 4 strains were used for this study, the type 1 strains 3 and 
11 and the type 2 strains 21 and 22. Strain 11 was used to determine 
the range of active concentrations of the compounds to be tested, and 
the following ranges were obtained :
IUdR : 15, 30 and 60 \sM
ara-C : 1.25, 2.5 and 5.0 pM
ara-A : 10, 20, 40 and 80 pM
No activity range could be found for ara-DAP below 80 pM and above this 
level toxicity was observed. It was noticeable at this stage that these 
ranges were higher than those found for plaque reduction assays. This 
point will be discussed in detail later.
The resultant titres of the treated samples were expressed as 
plaque forming units/ml, and the dose-response lines were plotted from 
the percentage of these figures compared with the virus control against 
the log of the compound concentration. As for the plaque reduction 
technique, the lines plotted for the individual strains (Fig. 3.24) were 
those from the original results before the best straight lines were fitted 
by the method of least squares. A representation of the results in this
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Fig. 3.24 Yield reduction dose-response lines obtained for ILIdR, 
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Fig. 3.24 (continued)
manner may be of assistance in explaining any abnormalities observed 
when straight lines were fitted.
The roost active compound against all four strains was again found 
to be ara-C, a result which is in agreement with the plaque reduction 
assays. However, the activities of both IUdR and TFT were much lower 
by this method, and were similar to that found for ara-A. When straight 
lines were fitted to the results and the slopes of the lines were 
calculated (Table 3.17) for each compound (Fig. 3.25), it was again 
obvious that the activity of ara-C covered a lower range of concentrations 
than did those of TFT, ara-A and IUdR, all of which were similar. The 
evidence for differential susceptibility between types will be discussed 
later.
In Table 3.17 there was a considerable variation in values. The 
mean slope was-115.5 with a standard deviation of 48.1. Within these 
values there were 3 which were outstandingly lower than the others, 
strain ll/TFT, strain 3/ara-C and strain 22/ara-A. The latter two may 
be partly explained by the fact that the values recorded for these lines 
were partly based on the tail of the line since all results fell below 
40% of the virus control. Strain ll/TFT, however, seems to be without 
explanation, as the values recorded fall quite well within the straight 
portion of the dose-response line.
It was noted earlier that lower activities were recorded for compounds 
when tested by reduction of yield as opposed to plaque reduction assays. 
This is clearly visible when the dose-response lines for both techniques 
were compared (Fig. 3.26). In the case of IUdR there was a considerable 
shift to the right in the yield lines. This shift was similarly large for 
TFT, but not so marked for ara-C, especially with the type 2 strain 3.
No significant differences were observed between the lines for ara-A.
TABLE 3.17 SLOPES OF DOSE-RESPONSE LINES OF STRAINS 3, 11, 21 AND 22 
OF HERPES VIRUS AGAINST IUdR, ARA-C, ARA-A AND TFT 
OBTAINED BY THE YIELD REDUCTION TEST
Strain 3 Strain 11 Strain 21 Strain 22
IUdR -75.11 -91.90 -93.58 -157.46
Ara-C -56.24 -155.15 -141.96 -214.86
Ara-A -110.62 -103.48 -87.95 -44.03
TFT -133.84 -55.09 -164.77 -162.77
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Fig. 3.25 The best fit dose-response lines obtained by the method 
of least squares for IUdR, ara-C , ara-A  and TFT against 
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This shift of sensitivities recorded by the two techniques was not 
found to be consistent, as shown by the similarities of the ara-A lines, 
which makes an explanation of the shift difficult to establish.
DISCUSSION
4.1 INTRODUCTION
The objectives of this work were to select and standardize the best 
techniques for the assay of anti-herpesvirus compounds and to apply them 
to obtain the relative potencies of the known active compounds IUdR, 
ara-C, ara-A, TFT and ara-DAP. A further aim was to investigate the 
comparative activities of these compounds against oral and genital strains 
of human herpes virus (types 1 and 2).
One problem in the field of antiviral chemotherapy which needs 
discussion is the lack of standardization in the expression of results, 
which is particularly evident in published work on herpes.
The progression of viral replication is normally monitored by a 
physical occurrence, such as the extent of infection in an infected animal 
or the extent of cytopathic effect in an infected culture. Antiviral 
activity is then expressed as a reduction in one of these effects. This 
may be observed directly, for example as a reduction in the extent of 
infection in herpetic keratitis, prolongation of survival time of 
intracerebrally infected mice, or as reduction in cytopathic effect in 
tissue culture. The effect may be placed on a quantitative basis by 
determining the concentration of compound required to give a minimal 
reduction (minimum inhibitory concentration), or a specified amount of 
reduction (ED50 or ED75). The ideal situation is when the response to a 
range of compound concentrations can be measured and expressed as a 
dose-response line, which gives a measure of the range of activity of a 
compound; also, the slope of such a line gives some indication of the 
efficiency of the compound as an antiviral agent.
The rabbit eye affords a rapid and simple site for evaluating activity
against herpes virus, but the expression of the results is subjective, 
since it relies upon individual assessment. Kaufman and Maloney (1963a) 
and Kaufman et al. (1970) graded eye infections merely, on the.area of 
ulceration on the cornea, although herpes virus also invades the 
conjunctiva. This was taken into account in the scoring methods of 
Underwood (1962) and Pavan-Langston et al. (1974), but the possible 
variation of the rate of progression of both corneal ulceration and the 
extent of conjunctivitis was not accounted for by these techniques.
Jones et al. (1968) quantified the technique by comparing titrations of 
virus in treated and control eyes. This method is essentially similar 
to the plaque reduction technique in tissue culture, but is less sensitive, 
because the maximum number of lesions under observation is only 16, as 
compared to an unlimited number of plaques which may be counted in plaque 
reduction tests. The plaque reduction test is therefore more accurate. 
However, the extent of infection of the eye may also be quantified by 
titrating the virus remaining in the eye after treatment and comparing 
this with the amount in control eyes (Jawetz et al., 1965).
In the present work the method of scoring devised by Corwin et al. (1963) 
was chosen because not only the extent of corneal and conjunctival 
involvement is recorded but also the rate of progression of such conditions 
is taken into account. Five signs of infection were recorded: opacity of
the cornea, area of the cornea involved, conjunctival redness, chemosis and 
discharge. Each of the five signs was graded either 1-4 or 1-3 according 
to intensity, and the scores of the signs involving the cornea were 
weighted by a factor of 10 and those for the conjunctiva were weighted 
by 2, because the corneal involvement was estimated to be of greater 
significance.
A widely used method for demonstrating antiviral activity against
herpes virus is the measurement of the increase in survival times of mice 
infected intracerebrally with herpes virus. Results have been presented 
as increases in survival times (Renis et al•, 1967) or as the mean survival 
time (Sloan et al •, 1968; Miller et al., 1969). This latter value is 
the mean survival time of the animals dying before the completion of the 
experiment, which is usually 21 days. No account is therefore taken of 
the surviving animals in which treatment has prevented virus replication 
reaching a lethal level, so that important information is arbitrarily 
discarded.
Occasionally the results are presented as the percentage of survivors 
(number of survivors/number of animals in a group). Without taking the 
survivors into account the mean survival times may not change significantly 
on treatment with increasing concentrations of drug. For example, in work 
quoted by Schabel (1968) a group of 20 mice infected intracerebrally with 
herpes virus was treated with 62 mg/kg/day ara-A; there were no survivors 
and a mean survival time of 7.3 days was recorded. A similar group of 
mice was treated with 250 mg/kg/day ara-A, with 6 survivors and a mean 
survival time of 7.5 days, in comparison with a control value of 5.6 days. 
These results do not show a dose-related effect, which would have been 
demonstrated had the survivors been taken into account. Some workers 
have expressed activity as the percentage increase in survivors (Allen and 
Sidwell, 1972; Sidwell et al., 1973). In this method the results of the 
test are not fully utilized since it does not take into account the 
prolongation of survival time of those treated animals which eventually 
die.
In addition to recording survival times, estimates have been made of 
the amount of virus remaining in the brain after successful treatment 
(Sloan et al., 1968; Miller et al., 1969). This effectively demonstrates
the fact that the multiplication of virus was being reduced by treatment, 
but the method seems to be too cumbersome for routine use.
In this present study the reciprocal of the survival time was taken 
as the response, r The reciprocals were taken because any animal which 
survived the course of an experiment had a notional survival time of 
infinity and if this were taken into account it would grossly distort 
the mean. The reciprocal of infinity is zero and by including the zeros 
the information contributed by the survivors is not discarded. The mean 
reciprocal survival times thus calculated gave response lines for treated 
and control groups of animals from which relative potencies were obtained 
as the horizontal distance between two lines. These values could then 
be compared with different compounds.
In tissue culture there are basically two systems by which anti-herpes 
virus activity may be assayed: by infectivity titrations or by plaque assay
techniques.
Infectivity titrations are normally carried out in tube cultures, 
the extent of the cytopathic effect being crudely graded 0-4. The differences 
thus recorded between control and treated cultures are taken as a measure of 
activity (Miller, 1967; Miller et al., 1968). Ehrlich et al. (1965) 
attempted to standardize the results obtained from tube tests by taking 
the mean of the results of tests at two levels of multiplicity of infection 
and calculating a value known as the virus rating from the formula.
where VR is the virus rating, the sura of control minus treated
scores for cultures infected with 100 TCID50 of virus, and y^lO the same 
value for cultures infected with 10 TCID50 of virus. Compounds giving a
virus rating of greater than 0.5 were considered to be active. Below 
this level the differences between treated and control cultures were not 
felt to be significant. However, this technique does not take into 
account the time which a culture takes to attain a desired degree of 
infection; for example, if a culture is examined at 48 hours and the 
control cultures have reached grade 4 cytopathic effect after only 36 hours 
any treated culture reaching grade 4 cytopathic effect subsequently is 
given a control minus treated value of zero, although some degree of 
activity has been shown. This method was originally developed for 
examining the activity of broth cultures after microbial fermentation, 
where the molar concentrations of the active substances were unknown. 
However, when the molecular weight of a compound is known much more 
meaningful results can be obtained, and it is therefore difficult to 
explain why this technique has been used for expressing the activity of 
known compounds against cytomegalovirus (Sidwell et al., 1972) and herpes 
virus (Sidwell et al., 1973). These workers not only detected antiviral 
activity by this method but used virus rating values for a comparison of 
activities, and as the result of this it is impossible to say how the 
activity of one compound compares with that of another.
Tube tests were used to some extent in the present work, and although 
reading the extent of cytopathic effect was subjective some meaningful 
results were obtained. Initially the mean of the reciprocal times to 
reach 50% cytopathic effect was compared for treated and control cultures 
to give relative potencies, but because evaluation of 50% cytopathic effect 
was difficult to standardize, the time of the delay in appearance of 
cytopathic effect was used as the definitive parameter, that is to say, 
the difference between the time when the control and treated cultures 
showed the first visible signs of cytopathic effect.
Plaque assay techniques have afforded far more information in the 
field of antiviral chemotherapy than the more subjective techniques 
already described.
The plaque inhibition test has been widely used for the initial 
detection of activity. This technique was first used against herpes 
virus by Herrmann (1961) to demonstrate the activity of IUdR, and has 
been used subsequently against herpes virus by Renis et al. (1967),
Miller et al. (1968), Person et al. (1970) and Lowry et al. (1971), and 
against herpes virus B by Miller (1967). From the size of the zone of 
protection much preliminary information on a compound may be obtained, 
such as the degree of activity and the toxicity of the compound.
Differences in type sensitivities can be detected by this method, but 
the measurement of zone diameters is open to subjective interpretation, 
on account of the indistinct boundary between the point of complete plaque 
suppression and the point where the compound exerts no protective effect. 
Also, the zone diameter depends on the rate of diffusion (which depends 
on molecular weight) and the solubility of a compound, which are unrelated 
to its antiviral activity. A greater degree of information was achieved 
from this technique by Person et al. (1970), who constructed dose-response 
lines for IUdR against herpes virus types 1 and 2 by varying the amount of 
compound on the disc and comparing the resultant zone diameters. This 
technique was not used in the present work because it was felt that more 
accurate lines could be obtained from plaque reduction tests.
The use of plaque counting to construct dose-response lines from 
yield reduction and plaque reduction techniques tends to give more 
reproducible results, and fortunately herpes virus plaques quite readily 
in a range of cell lines. Good yield reduction dose-response relationships 
were demonstrated by de Rudder and Privat de Garilhe (1965) and
Renis et al. (1967). Many workers have used plaque reduction but have 
made comparisons of activity using concentrations expressed as pg/ml 
and not in molarities (Rapp, 1964; Buthala, 1964; Jawetz et al•, 1965; 
Miller, 1967; Miller et al., 1968; Zaky et al., 1975). If the molecular 
weight of a compound is not taken into account true comparisons cannot be 
made, for a compound with a molecular weight of twice one with which it is 
to be compared would appear to have half the activity expressed as pg/ml, 
if the activity at the molecular level was the same. It should be 
pointed out, however, that it is.valid to quote doses for animals and 
man in milligrammes (i.e. mg/kg) where the dose is calculated in proportion 
to the weight of the animal.
Many workers have also failed to plot dose-response lines and only 
quote their results in tabular form, although their figures appear to give 
good dose-response lines (Rapp, 1964; Buthala, 1964; Jawetz et al., 1965; 
Miller, 1967; Miller et al., 1968). Much more information can be obtained 
from the lines, for example the ED50 or ED75 values, which give a rapid 
estimate of the relative and absolute activities of the compounds.
Both yield reduction and plaque reduction techniques were used in 
this work and the dose-response lines constructed from compounds tested 
in molar concentrations have allowed some very illuminating conclusions 
to be drawn. Bearing this in mind it seems surprising that little use 
has been made of such sensitive techniques by other workers in the field.
Because of the asymptotic nature of dose-response lines it would seem 
preferable to use probit analysis for fitting straight lines through the 
values obtained. It should be pointed out, however, that the concentrations 
used were selected to fall within the straight portion of the lines, and in 
the fitting of straight lines by the method of least squares any values 
which fell on the tailing off portion of the lines were not used.
Minimum inhibitory concentrations are frequently used to express 
antiviral activity and may be determined by any of the techniques previously 
described, although for herpes virus they are more frequently determined 
in tube cultures (de Lavergne £t al., 1965; Walker et al., 1971;
Fiala et al., 1972a, b; Fiala et al., 1974). The minimum inhibitory 
concentration is the lowest concentration at which an antiviral effect 
can be detected. Although this gives a finite measure of activity it 
does not take into account the slope of the dose-response line. Therefore 
falsely high activities may be recorded for compounds which give low slopes 
for dose-response lines or vice versa. In the present work the minimum 
inhibitory concentration was used only for evaluating the results of the 
gradient plate plaque reduction test.
4.2 TYPING OF STRAINS OF HERPES VIRUS
Pock size on the chorioallantoic membrane was chosen as the 
preliminary and definitive typing method for the 24 strains originally 
received for this work. The majority of the strains were of very low 
passage level, being freshly isolated from either oral or genital sources. 
There were, however, three exceptions, strains 11, 12 and 31, none of which 
were fresh isolates and whose passage histories were not fully known.
The pocks produced by all the strains were measured and compared.
The measurements fell into two clear cut groups; ^ 0.4 mm and ^0.6 mm; 
no strains produced pocks within the range 0.4 - 0.6 mm. These results 
are in agreement with those of other workers in the field (Nahmias et al., 
1968). Those strains producing pocks smaller than 0.4 mm were found to 
be of oral origin (type l), and those with pocks greater than 0.6 mm were 
found to be genital isolates (type 2). The multiple passage of the 
strains 11, 12 and 31 did not result in any unexpected pock sizes; the 
strains 11 and 12 which were expected to be type 1 produced typical small 
pocks, and strain 31 produced large pocks indicative of type 2. Although 
for each strain there were variations in pock size these did not fall 
outside the designated ranges.
This technique is probably the most frequently used method of typing 
and the results obtained have been found reliable. In a recent review 
(Plummer et al., 1974) pock size determinations were compared with 
biochemical and serological methods of typing, and complete agreement 
was found for the types determined by each technique. It was therefore 
felt to be unnecessary to use any other typing technique, in particular 
the kinetics of neutralisation.
As much of the quantitation of antiviral activity was performed in 
tissue culture it was felt that it would be of interest to examine the
cytopathic effects produced by the chosen strains (2, 3, 5, 6, 11, 21,
22, 24, 27 and 28) in VERO cells. Leinikki (1971) found that type 1 and 
type 2 strains of herpes virus produced plaques of different sizes in 
VERO cells, and therefore plaque size and cytopathic effects were examined 
in the present work. Type 1 strains produced small focal plaques 
0.4 - 0.65 mm in diameter, whereas type 2 strains produced larger, more 
open plaques 0.65 - 1.0 mm in diameter. The standard deviation of the 
plaque sizes measured was approximately 20%, which meant that the 
difference found between type 1 strain 3 and type 2 strain 27 was not 
significant. However, it was strain 27 that was found to be atypical, 
since it produced the smaller focal plaques normally associated with 
type 1 virus. This was confirmed when the cytopathic effects were 
examined. Strains 2, 3, 5, 6, 11 and 27 produced a proliferative effect 
where infected cells were found heaped on top of one another, whereas 
strains 21, 22, 24 and 28 produced a non-proliferative effect where 
infected cells pulled apart, producing gaps or plaques in the monolayers.
Although these two techniques essentially confirmed the results 
obtained by pock size determinations, they could not be used with 
confidence to determine the type of strains of unknown origin. However, 
an insight was obtained as to the behaviour of the strains in vitro.
4.3 APPRAISAL OF THE TECHNIQUES USED
4.3.1 Animal studies
The compounds IUdR, ara-C, TFT and ara-A are all of known antiviral 
activity and are frequently used in clinical practice both systemically 
and topically. Therefore it was felt necessary to compare the efficacies 
of these compounds in addition to the new compound ara-DAP under both 
systemic and topical usage in vivo. Subcutaneous treatment of 
intracerebrally infected mice was chosen as the systemic method and the 
treatment of experimentally induced keratitis as the topical method.
Only two compounds, ara-A and ara-DAP, were found to be of sufficient 
activity in mice to require study in any depth. In man ara-C and IUdR 
are known to be effective when given by continuous intravenous infusion 
and therefore they would be expected to be active under experimental 
conditions. Their lack of activity may be attributed either to their 
short half-lives after a single dose, or to the failure of the compound 
to cross the blood-brain barrier (Table 4.1). It is clear from the 
table that the half-lives of the compounds are short, and all compounds 
except TFT are readily broken down; 35% of TFT may be recovered unchanged 
in the urine 15 minutes after administration. Only ara-A is known to 
cross the blood-brain barrier, but one may assume that ara-DAP also crosses 
it because of the similar activity to ara-A demonstrated in mice, and the 
similarity in chemical structure of ara-A and ara-DAP. It is possible 
that the blood-brain barrier may be damaged during encephalitis, which 
would afford pasy entry of compounds, but this is not supported by the 
lack of activity shown for IUdR.
In man the compounds are normally infused over a period of several 
hours each day. This method of treatment cannot be conveniently used in 
mouse experiments. The method of dosing adopted, however, provides a
TABLE 4.1 THE IN VIVO PROPERTIES OF IUdR, ARA-C, ARA-A, TFT 
AND ARA-DAP
Compound Reference
Plasma half- Ability to 
Species Route (minutes) cross blood/
brain barrier
IUdR
Ara-C
Ara-A
TFT
Creasy et al. (1964) 
Ch'ien et al. (1973) 
Rogers et al. (1969)
Man
Man
Monkeys
dogs
l.v.
i.v.
i.v.
30-60
90
30
No
No report 
Yes 
No report
Ara-DAP Elion et al. (1975) Mice s.c. >15 No report
satisfactory method for examining the activities of potential anti-herpes 
compounds providing that they are not too rapidly metabolized and are 
capable of reaching the site of infection. The use of the method is 
therefore limited to the examination of compounds which fulfil these 
criteria.
The treatment of experimental keratitis in the rabbit eye presents 
none of these problems. The avascular nature of the cornea reduces the 
effect of metabolism of the compound, and there are no barriers to cross 
except possibly penetration into the eye for the treatment of deeper 
infections. All compounds examined were found to show some degree of 
activity against established infections, and this was found to be an 
effective method of detecting topical antiviral activity in vivo. The 
clinical situation is simulated by allowing the infection to become 
established and the technique therefore gives an indication of the 
performance of the compound in clinical use.
Problems were encountered in finding strains of herpes virus which 
would cause reproducible infections of the cornea, but finally strains 11 
and 21 were found satisfactory for the purpose. Both gave rise to 
extensive infections, with the type 2 strain 21 showing a tendency to 
produce deeper involvement. The relative activities of the compounds 
were compared by this technique, but the potential error arising from 
subjective assessment of infections does not permit satisfactory quantitative 
comparisons to be made.
Neither of the in vivo techniques has provided the amount of 
information necessary to give quantitative data on type sensitivities 
and relative activities of the compounds. Therefore jln vitro techniques 
were sought for the purpose of developing more quantitative test 
methods.
4.3.2 Tissue culture studies
In tissue culture there are two basic methods which may be employed 
for assaying antiviral activity: infectivity titrations and techniques
dependent on plaque formation.
Infectivity titrations were performed in both tube cultures and in 
microtitre plates. Activity was readily detected by both procedures 
but quantitation of the activity was difficult. Because of the subjective 
nature of the assessment of the results numerous replicates were required, 
which made the tube test in particular rather time consuming. Microtitre 
plates were much simpler to prepare and large numbers of replicates could 
easily be set up, but unfortunately the cells seeded in such plates failed 
to settle out as a normal monolayer, and became grouped around the periphery 
of the wells, probably due to surface tension effects. Difficulty was 
therefore experienced in the reading of such cultures, which increased the 
subjective nature of the technique and only limited use was made of it.
A number of techniques have been developed which involve the plaquing 
ability of herpes virus. The plaque inhibition test is now widely accepted 
as a method for detecting antiviral activity as well as demonstrating any 
toxicity for the cell sheet. The technique can be quantified by the 
measurement of the zones of toxicity and inhibition, neither of which are 
affected by variations in the titre of the inoculum. The size of the zones 
was found to vary proportionally with the amounts of compound on the disc, 
and therefore some quantitation may be achieved by producing dose-response 
lines. This technique was used to test five type 1 and five type 2 strains 
and very reproducible results were obtained with all compounds except 
ara-DAP, which only showed very low activity. This may have been due to 
the low solubility of ara-DAP or possibly a slow rate of diffusion.
An extension of this work was the gradient plate plaque reduction test,
by which it was hoped to obtain minimum inhibitory concentrations and 
preliminary indications of the activity ranges of the compounds. Two 
technical problems were encountered which made the technique unreliable. 
Firstly, because of the low concentration of the agarose it began to lift, 
causing a merging of control and test overlays, leading to an uneven cut off 
point of plaque formation. Also, a curved cut off point was observed as 
the result of a meniscus effect. The cultures were also cumbersome to 
prepare and therefore little use was made of this technique.
The construction of dose-response lines by plaque-dependent methods 
was found to be the most sensitive means of assaying antiviral activity.
Yield reduction experiments based on single cycle conditions were 
performed and the virus yields after incubation were titrated by the 
plaque assay method. Titres were then expressed as a percentage of the 
control yield, and the values were used for constructing dose-response 
lines. This technique was found to give good lines and in addition 
proved that the compounds were not merely preventing plaque formation 
but were actually inhibiting virus replication. This method was found, 
however, to be a time consuming procedure. A more rapid and sensitive 
technique for producing dose-response lines was found to be the plaque 
reduction test, in which cultures infected with a known amount of virus 
were treated with a range of compound concentrations under plaquing 
conditions. The plaque counts obtained were then plotted as a percentage 
of the control value to give a dose-response line. This technique was 
found to be simple to perform and the results were easily interpreted 
and very reproducible.
Taking the techniques used in this work into consideration, the 
plaque reduction test was found to be the most sensitive method for 
comparing antiviral activities. Yield reduction tests were found to be
similarly reliable but less sensitive than the plaque reduction test 
and also too time consuming for routine use. The subjective assessment 
of the delay in cytopathic effect used in infectivity titrations was found 
to be unsatisfactory for comparing type sensitivities, although compound 
activities were readily and rapidly demonstrated. Detection of activity 
by the plaque inhibition test took longer to carry out because of the 
time taken to produce plaques, but more information about the compounds 
was obtained. Therefore the plaque inhibition test was preferentially 
used for detecting activity.
The animal models used indicated antiviral activity adequately, but 
did not give sufficient information for the comparison of type sensitivities.
4.4 COMPARISON OF ACTIVITY AND SENSITIVITY
4.4.1 Mouse tests
Anti-herpes virus activity in mice was found with only two compounds, 
ara-A and ara-DAP, and although minimal increases in survival times were 
recorded for IUdR and TFT the increases were felt to be insufficient to 
warrant any further investigation. Ara-A and ara-DAP were shown to have 
similar activities against the type 1 strain 11, giving relative potencies 
of 0.83 and 0.89 respectively, whereas against the type 2 strain 31 
ara-DAP was found to be the more active, with a relative potency of 1.70 
as opposed to 0.94 for ara-A. This indicates that the type 2 strain 31 
was markedly more sensitive to ara-DAP than the type 1 strain 11. Type 
sensitivity differences were not found with ara-A. The difference in 
type sensitivity shown between strains 11 and 31 by ara-DAP was surprising, 
as from published information the reverse would have been expected.
However, investigation of the significance of this observation was limited 
by shortage of the compound, which prevented the sensitivities of further 
strains from being examined by this technique.
4.4.2 Rabbit eye tests
All compounds tested by this method showed anti-herpes activity, 
but without the use of many more animals it would be impossible to state 
which compound was the most active. Activity was only tested against 
two strains (11 and 21). All compounds showed excellent activity against 
the type 1 strain 11, with almost complete cures being achieved in every 
case. Activity was not so marked, however, against the type 2 strain 21. 
Limited successes were recorded for IUdR, ara-C and TFT, and ara-A and 
ara-DAP were less effective, since only one animal of the two used for 
each compound showed any degree of compound activity.
It must be noted that type 2 virus tends to produce a more neurotropic 
infection, by penetrating the eye and eventually passing to the brain.
This deeper involvement is not taken into account by the method of scoring 
used, but it was indicated in Table 3.7, by the observation of iritis.
In the cases of ara-A and ara-DAP, however, the corneal infection 
was not eradicated, and therefore this may be taken as genuine lack of 
activity against the type 2 strain. TFT would have been expected to 
give better results under these conditions because of its known ability 
to penetrate the eye; IUdR, ara-C and ara-A are unable to penetrate the 
eye, and no information on ara-DAP has been published.
From these results, therefore, it would appear that the type 1 
strain 11 was more sensitive than the type 2 strain 21 to chemotherapy, 
but with the limitation that the courses of the two infections are not 
identical.
4.4.3 Tube culture tests
Two techniques were examined for suitability for use in this work, 
and the increase in the delay in appearance of cytopathic effect with 
decreasing virus concentration was chosen as the criterion to be studied. 
Varying concentrations of each compound were tested to find levels which 
produced similar responses, and these were found to be: 2.5 pM for ara-C,
10 pM for IUdR, ara-A and TFT, and 20 pM for ara-DAP; this therefore 
indicates that ara-C was the most active compound tested.
The sensitivities of the strains were examined with infective doses 
of 1, 10 and 100 TCID50/ml, and the decreasing orders of their sensitivities 
are shown in Table 4.2. The results for 100 TCID50/ml were not given, 
as they failed to give sufficiently large delay values to afford any 
significant information. Study of this table shows that no strain can be
TABLE 4.2 STRAIN SENSITIVITIES SHOWN IN DECREASING ORDER FDR 
IUdR, ARA-C, ARA-A, TFT AND ARA-DAP TESTED AT 
VIRUS INPUT CONCENTRATIONS OF 1 AND 10 TCID50/ml.
IUdR
1* 10
Ara-C 
1 10
.
Ara*
1
-A
10 1
TFT
10
Ara-DAP 
1 10
24 3 3=6 22 3=6 11 11 11 3 6
27 5 11 3=6 11 22 6 22 11 3
3 24 22 24 27 24 22=27 27 6 11=22
22 2 21 28=11 22=24 27 5=3 5 22 27
6=11 27 28 21 5 5 28 3 24 21
21 6 27 27 2 6 2 6=24 2 5
5=2=28 28 5 5 28 2 21 28=2 5=28 2
21 2 2 21 3 24 21 27 28
11 24 28=21 21 24
22
* Virus inoculum TCID50/ml
satisfactorily typed by its response to an antiviral agent. The 
sensitivities of the strains of each type were found to overlap, but 
certain strains were found to be quite frequently the most sensitive 
(3, 6, 11, 22 and 27). The strains 2, 5, 21, 24 and 28 were generally 
of lower sensitivity, although again there was an overlap, not only between 
compounds but between the concentrations of virus tested. For example 
strain 5 was the least sensitive strain when tested at 1 TCID50/ml 
with IUdR, but at 10 TC1D50 it was found to be the second most sensitive 
strain. Such variations may only be explained by the intrinsic 
insensitivity of a test in which times have to be estimated.
4.4.4 Microtitre plate tests
The microtitre plate test was used to substantiate the results 
obtained from tube culture tests, but because of technical problems 
previously described, few meaningful results were obtained. The relative 
compound activities were determined against the four strains tested 
in the same way as in tube tests. Similar responses were obtained 
at 2.5 pM for ara-C, 5.0 pM for TFT, 10 pM for IUdR and ara-A, and 20 pM 
for ara-DAP, and this order may therefore be taken as indicating decreasing 
activity. From the results obtained no type differences could be detected, 
and the variability of the results led to the discontinuation of this 
technique.
4.4.5 Plaque inhibition tests
This technique has been described as a detection method, but some 
information about the sensitivities of the strains and compound activities 
was obtained. All compounds were tested with the same amount of compound 
(50 pg/disc), and ara-C was clearly found to be the most active, with
resulting zones of protection of between 50 and 85 mm. Ara-DAP was 
found to be the least active compound by this technique, with only 4 strains 
giving zones that could be measured. Comparisons between the activities 
of ara-A, IUdR and TFT could not be made since the zones produced by these 
compounds were similar and the molecular weights and solubilities were not 
taken into consideration. Valid comparisons of strain sensitivities for 
individual compounds could be made, however (Table 4.3). All strains 
have been listed according to their mean zone diameter with a class 
interval of 5 (i.e. 0 - 4  mm, 5 -  9 ram, etc.). Strains giving diameters 
within the same class were listed in the order of increasing sensitivity.
By this method, however, the difference in sensitivity between two strains 
placed in separate classes may be exaggerated, but listing the strains 
individually was felt to be less valid because of subjective error in the 
measurement of zone diameters.
Differences in type sensitivity were clearly shown in the case of 
IUdR and ara-C, with the exception of strain 27 with IUdR, which gave a 
typical type 1 response. It was noted, however, that strain 27 produced 
plaques of a type 1 nature. Type differences were not found with the 
remaining compounds since the mean zone diameters were found to overlap, 
although there was a tendency for type 2 strains to be less sensitive. 
Strains 2 and 5 were generally found to be the most sensitive and strains 21 
and 28 the least sensitive. To distinguish between strains when their 
mean zones of protection vary by as little as 0.5 - 1.0 ram is hardly 
possible, and therefore differences can only be claimed when zones vary 
by more than 5 mm.
Poor results were obtained with ara-DAP by this technique, since 
only 4 strains showed zones of protection; this may be accounted for by 
the very low solubility of this compound, although ara-A also has a low
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solubility. Zones of protection were obtained with ara-DAP but they 
were less than 5 mm in diameter and therefore impossible to measure 
accurately. The diffusion rate of ara-DAP may also be low, thus 
preventing sufficient compound from reaching the infected cells.
4.4.6 Gradient plate plaque reduction tests
Technical problems prevented the expected results being obtained 
from this method, and therefore only the sensitivities of two strains,
11 and 22, were examined. Ara-C was found to be the most active compound, 
with minimum inhibitory concentrations of about 5 pM; for TFT values of 
about 50 pM were obtained, and for ara-A about 70 pM. A type difference 
was observed with IUdR, with the type 1 strain 11 giving a minimum inhibitory 
concentration of 69.5 pM and the type 2 strain 22 a value of 82.5 pM, 
but upon statistical examination of the original values obtained by the 
t test this difference was not found to be significant. Therefore it 
may be concluded in the absence of results from further strains that 
no type differences could be observed by this technique.
4.4.7 Plaque reduction tests
This technique has proved to be very sensitive and has afforded 
much of the information required for this study. Very high activities 
were recorded for both ara-C and IUdR, with ara-C being more active 
against type 2 strains than IUdR. TFT was found to be the next most 
active compound, followed by ara-A, with ara-DAP displaying the least 
activity. These are overall observations based on 10 strains of herpes 
virus, and variations did occur from strain to strain. Therefore it 
would appear that the pyrimidine compounds were more active than the 
purine nucleosides.
The sensitivities of individual strains were determined by dose- 
response lines, and from these ED50 values were obtained (Fig. 4.1).
From the results displayed in this manner the type differentiation 
demonstrated by plaque inhibition tests for IUdR was maintained, with 
strain 27 again being associated with the type 1 strains. However, 
no type differences were observed for ara-C, therefore failing to 
substantiate the previous finding. Strains 11, 6, 3 and 27 were 
closely grouped, with higher sensitivities than the strains 24, 22, 5, 2,
28, and 21, all strains being listed in order of decreasing sensitivity.
The slopes of the dose-response lines for strains 21 and 28 were slightly 
lower than those of the majority of strains, and this may account for 
their low sensitivities. Similarly strain 24 gave a low slope when 
tested against IUdR, which gave rise to a lower sensitivity than expected.
A great deal of overlap was observed between the type sensitivities 
obtained with ara-A, which is evident when the strains are arranged in 
decreasing order of sensitivity: 2 > 5 > 24 > 11 > 6 = 22 > 3 > 2 7  > 2 8  >21.
Strains 2 and 5 were again found to be the most sensitive and strains 21 
and 28 were the least sensitive. The results obtained with TFT gave a 
similar degree of overlap, but surprisingly strains 2 and 5 gave low 
sensitivities, although this may be explained by the low slopes of the 
dose-response lines. Strains 21 and 28 appeared to be insensitive to 
TFT at the concentrations tested (0.5 - 80 pM), above which toxicity 
became evident. The order of strain sensitivities was therefore :
11 > 22 > 6 > 3 > 24 > 27 > 2 > 5.
Similarly with ara-DAP no dose-reSponse lines were obtained for 
strains 21 and 28, and also the results obtained for strain 27 were not 
significantly different from the virus control to enable a line to be 
plotted. The order of strain sensitivity was therefore found to be:
Fig. 4.1 Comparison of ED50 values obtained from
plaque reduction test dose-response lines
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11 > 3  > 2  > 5 > 22 > 24 > 6. The values for strains 22, 24 and 6, 
however, were obtained by extrapolating the dose-response lines, thus 
giving estimated ED50 values. For these strains only results with high 
percentages of the virus controls were obtained, producing dose-response 
lines with exceptionally low slopes from which these high ED50 values 
were obtained.
Differences in type sensitivity have not been consistently demonstrated 
by this technique. With the exception of strain 27 type differences were 
observed with IUdR, but with the remaining compounds the overlap of ED50 
values prevented such a conclusion from being made. A study comprising 
only the four strains 2, 5, 21 and 28 would show a type difference, which 
emphasizes the fact that as many representative strains as possible from 
each type should be used before any conclusions as to differential sensitivity 
can be made.
4*4.8 Yield reduction tests
Only four strains (3, 11, 21 and 22) were used for this work, and 
they were chosen because of their ability to grow to high titre, so that 
high multiplicities of infection could easily be obtained. Under single 
cycle conditions ara-C was clearly found to be the most active compound; 
ara-A, TFT and IUdR were all found to have similar activities, but lower 
than that of ara-C, and no activity was found with ara-DAP, because of 
its toxic properties above 80 |jM. The ED50 values obtained from the 
yield reduction dose-response lines were compared as for the plaque 
reduction results, and are shown in Table 4.4.
With such a limited number of strains, it was difficult to differentiate 
between types, but some information was obtained on individual strain 
sensitivities. No type differences were found with IUdR, which is
TABLE 4.4 L°Gl0 E050 VALUES OBTAINED WITH IUdR, ARA-C, ARA-A AND TFT
AGAINST STRAINS OF HERPES VIRUS BY YIELD REDUCTION EXPERIMENTS
Strain Type IUdR
Compound 
Ara-C Ara-A TFT
3 1 1.05 -0.18 1.39 1.18
11 1 1.29 0.46 1.245 1.29
21 2 1.18 0.34 1.29 1.305
22 2 1.46 0.55 0.85 1.65
inconsistent with the results of both plaque inhibition and plaque 
reduction tests. The order of decreasing strain sensitivity was:
3 > 2 1  > 11 > 22. The same order of strain sensitivities was found 
with ara-C, with strain 3 having an exceptionally low ED50. Strain 22 
was found to be much more sensitive than expected when tested against 
ara-A, the order of strain sensitivities being 22 > 11 > 21 > 3.
With TFT the order of strain sensitivities was 3 >.11'>21 >22. The 
activity recorded for TFT against strain 21 contradicts the result given 
by the plaque reduction method, but it may be an indication of the greater 
sensitivity of the yield reduction method.
One most striking fact when comparing the results obtained by yield 
reduction with those obtained by plaque reduction assays was that the 
ED50 values obtained for the latter method were much lower than those 
obtained by yield reduction (Fig. 3.26), with one notable exception, the 
results obtained for ara-A, which were identical by each method. This 
cannot be explained by differences in sensitivity between the two techniques, 
although one would expect yield reduction assays to be more sensitive than 
plaque reduction assays. The explanation of this phenomenon may be based 
on the metabolism of these compounds. All are rapidly metabolized, but 
ara-C, TFT and IUdR give rise to inactive metabolites, whereas in the 
case of ara-A the first breakdown product is 9-p-D-arabinofuranosyl- 
hypoxanthine (ara-Hx), which is active against herpes virus. This may 
therefore account for higher activities being recorded by the yield 
reduction method than expected, because the active hypoxanthine analogue 
would replace the rapidly broken down ara-A. Such activity would not be 
maintained for the other compounds which are broken down to inactive 
metabolites.
4.5 CONCLUSIONS
Over the past 20 years there have been numerous reports on the 
activities of IUdR, ara-C, ara-A and TFT but none have attempted to show 
which of these compounds is the most effective. Until recently their 
only application has been in topical treatment, where quite high 
concentrations have been used without undue regard for toxicity. The 
increasing demand for systemic usage, however, indicates a need for 
knowledge of the relative activities of these compounds and a basis for 
comparisons with new antiviral compounds in the field. In this study 
attempts have been made to compare the activities of these compounds, 
and ara-DAP, by various test methods. Ara-C has been consistently found 
to be the most active compound, followed by IUdR and TFT with lower but 
similar activities. Finally ara-A and ara-DAP gave the lowest activities 
but again similar by the majority of methods. The activities of these 
compounds were not compared in vivo because of the insensitivity of such 
techniques.
Differences in type sensitivity were demonstrated in studies in the 
rabbit eye; the type 1 strain tested was found to be more sensitive than 
the type 2 strain. These differences were not observed in the mouse 
work. Taking into account the differences in the nature of infection 
in the rabbit eye, and that only one strain of each type was tested, 
these results must be interpreted with care. In attempts to clarify 
the situation use was made of tissue culture techniques. Infectivity 
titrations failed to give reliable results and therefore attention was 
directed towards plaque dependent techniques, since the strains of virus 
used readily formed plaques in VERO cells.
Differences in type sensitivity were found in the case of IUdR by 
both plaque inhibition and plaque reduction techniques but not in yield
reduction studies. Differences were also found with ara-C in plaque 
inhibition studies but not by plaque reduction or yield reduction techniques. 
Susceptibility differences were not observed with ara-A, TFT or ara-DAP.
In the various reports on the susceptibility of types of herpes virus, 
IUdR has most frequently been shown to vary in its activity. This claim 
has been essentially verified in this work, but the question remains as to 
why differences were not detected by the more sensitive yield reduction 
technique. Differences in type sensitivity were not observed with any 
of the compounds tested by the yield reduction method, although only two 
strains of each type were examined. It was previously suggested that 
differences in the nature of type 1 and type 2 infections in the rabbit 
eye might be the cause of the differences in type sensitivity which were 
found. A difference in the nature of infection could therefore be the 
cause of the differences found with IUdR in tissue culture, differences 
which may not be detected under single cycle conditions. If this be 
the case, however, one would expect that this difference would be common 
for all the compounds tested, but this was not observed, therefore it must 
be concluded that variations in type sensitivity can be demonstrated with 
IUdR, but not with ara-C, ara-A, TFT or ara-DAP, where there was too 
great a degree of overlap in sensitivities to distinguish between types.
It must be borne in mind that these sensitivities may vary depending on 
the cell type used, but VERO cells were found to be consistent in their 
responses to infection and subsequent treatment. It is therefore probable 
that these findings could be substantiated in other cell lines.
It is important to know how a compound will fare against different 
types of herpes virus, especially in view of the growing concern over 
genital herpes and its possible complications. Therefore it is necessary 
to have a reliable and rapid method of evaluating possible therapeutic agents.
The overall impression from this work is that the plaque reduction test 
adequately fills this role, and gives rapid and reliable estimations of 
both relative activities of the compounds tested, and indication as to 
type sensitivity.
Finally, therefore, it is concluded that ara-C is the most potent 
in vivo anti-herpes virus compound known at present; also that type 1 
strains are more sensitive to IUdR than type 2 strains, but that this 
difference is not shown by ara-C, ara-A, TFT or ara-DAP. A tendency for 
certain type 2 strains to be less sensitive was observed, but the difference 
was not nearly so clear cut as reports in the literature would lead one 
to suppose.
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